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ABSTRACT

THE IMPACT OF A LIFESTYLE INTERVENTION ON RISK FACTORS OF
CARDIOVASCULAR DISEASE AND TYPE II DIABETES AMONG AT-RISK
HISPANIC WOMEN

MAY 2022

KATHRYN ANNE WAGNER,
B.A., UNIVERSITY OF MASSACHUSETTS – AMHERST
M.S., UNIVERSITY OF MASSACHUSETTS – AMHERST
Ph.D., UNIVERSITY OF MASSACHUSETTS – AMHERST
Directed by: Dr. Lisa Chasan-Taber

Cardiovascular disease and type 2 diabetes are global epidemics affecting
approximately 127 and 21 million people in the U.S., respectively. Women who are
overweight, obese or who develop glucose intolerance during pregnancy represent highrisk groups for the development of cardiovascular disease and type 2 diabetes. Hispanic
women are both more likely to begin their pregnancies as overweight or obese and have a
higher prevalence of type 2 diabetes, compared to non-Hispanic whites. However, prior
lifestyle interventions have largely been limited to non-Hispanic whites. Therefore, this
research assessed how culturally tailored lifestyle modification may affect cardiovascular
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disease and type 2 diabetes risk factors among at-risk Hispanic women using data from
Estudió PARTO and Proyecto Mamá, two randomized controlled trials of pregnant
Hispanic women in western Massachusetts.
Chapter 1 examined the impact of a lifestyle intervention on postpartum
cardiovascular disease risk and insulin resistance biomarkers among Hispanic women
with abnormal glucose tolerance. The Lifestyle Intervention (LI) arm experienced
clinically significant lower levels of insulin than the comparison Health and Wellness
arm (HW), statistically lower levels of HDL cholesterol and TNF-a, and no differences in
all other cardiovascular disease risk and insulin resistance biomarkers.
Chapter 2 examined the impact of a lifestyle intervention on pregnancy and
postpartum cardiovascular disease risk and insulin resistance biomarkers among
overweight and obese Hispanic women. The lifestyle intervention did not lead to a
significant difference in change over the pregnancy and postpartum follow-up time in
most cardiovascular disease risk and insulin resistance biomarkers, with the exception of
higher LDL cholesterol concentrations among the LI arm compared to the HW arm.
Lastly, Chapter 3 examined the impact of a lifestyle intervention on postpartum
weight retention among overweight and obese Hispanic women. The LI arm had a
clinically significant 5.5-fold higher odds of meeting postpartum weight reduction goals,
at 12 months postpartum and a 5 kg smaller increase in weight at 6 months postpartum,
compared to the HW arm.
In conclusion, a lifestyle intervention had beneficial impacts on numerous
cardiovascular disease risk and insulin resistance biomarkers, including insulin, and
postpartum weight retention in this high-risk Hispanic population.
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CHAPTER I
THE IMPACT OF A LIFESTYLE INTERVENTION ON POSTPARTUM
CARDIOVASCULAR DISEASE RISK AND INSULIN RESISTANCE
BIOMARKERS AMONG HISPANIC WOMEN WITH ABNORMAL GLUCOSE
TOLERANCE DURING PREGNANCY

A. Background and Significance
1. Public Health Impact of Prenatal and Postpartum Cardiovascular Disease Risk
Factors and Insulin Resistance Biomarkers
Systolic and diastolic blood pressure, lipid profiles (total cholesterol, low density
lipoprotein [LDL] cholesterol, high density lipoprotein [HDL] cholesterol, and triglyceride
concentration), C-reactive protein, and the albumin-to-creatinine ratio are markers of
cardiovascular health (1). High blood pressure, total and LDL cholesterol, triglycerides, Creactive protein and albumin-to-creatinine ratio and low HDL cholesterol are associated
with increased incidence of cardiovascular disease (e.g., coronary heart disease, stroke,
atrial fibrillation, and atherosclerosis), which can lead to sudden cardiac death or heart
failure later in life (2). Cardiovascular disease is the most common cause of mortality in
the US (2).
Among Hispanic women in the US, between 2011 and 2014, approximately 30.7%
had high blood pressure and 41.2% had high total cholesterol (i.e., total cholesterol levels
of 200 mg/dL or higher) (3). Hispanic women of Puerto Rican descent have a significantly
higher prevalence of hypertension and hypercholesterolemia and are more likely to have at
least three cardiovascular risk factors than Hispanic women of other descents (i.e., Cuban,
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Dominican, Mexican, Central and South American) (4). Additionally, Hispanic women in
the US have a greater likelihood of having elevated C-reactive protein levels (5) and
albumin-to-creatinine ratio when compared to non-Hispanic white women (6). In U.S.
Hispanic women, heart disease is the second leading cause of death (7). Between 2011 and
2014, 33.3% of Hispanic women had cardiovascular disease, which was the cause of death
in approximately 23,350 Hispanic women in 2015 (3). However, Hispanic women of
Puerto Rican descent are more likely to have self-reported cardiovascular disease when
compared to Hispanic women of other descents (4). An adverse cardiovascular risk factor
profile during pregnancy and the postpartum period are associated with a higher risk of
developing cardiovascular disease in the future (8). Hispanics are thought to be particularly
susceptible to cardiovascular disease due to lower average socioeconomic status and
education levels, differences in cultural factors, stress related to discrimination and barriers
to healthcare related to language (9).
One of the cardiovascular changes during a normal pregnancy is a decrease in
peripheral resistance of the blood vessels. Therefore, during pregnancy systolic blood
pressure generally stays the same and there is a small decrease in diastolic blood pressure.
Blood pressure usually returns to pre-pregnancy levels during the postpartum period
(10,11). Although the causes are not well understood, in some women blood pressure can
increase during pregnancy (12). Gestational hypertension leads to the development of
preeclampsia (blood pressure  140/90 mmHg and presence of protein in the urine), which
is a disorder that can lead to multi-organ failure in pregnant women (12). Women with
preeclampsia are more likely to have high blood pressure during the postpartum period
(13).
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Total and LDL cholesterol also typically increased during pregnancy, with an
estimated 50% increase in total cholesterol, due to increased need for production and
function of hormones and fetal development (14,15). Additionally, a two- to fourfold
increase in triglyceride concentrations occurs during pregnancy, with levels returning to
pre-pregnancy concentrations during postpartum (15). Women with lipid profiles
exceeding the normal increases observed during pregnancy could also experience
hyperlipidemia into the postpartum period, and therefore increase the risk of
atherosclerosis later in life.
Prior studies have observed that up to 50% of postpartum women had elevated Creactive protein levels 12 months after childbirth, with low socioeconomic status serving
as a significant predictor (16). Elevated C-reactive protein levels have been associated with
a number of inflammatory conditions, including cardiovascular disease and atherosclerosis
(17). However, all cardiovascular risk factor biomarkers typically return to pre-pregnancy
levels within 3 months postpartum (18–21).
Elevated insulin, glucose, HbA1c, leptin, tumor necrosis factor alpha (TNF-a),
fetuin-A and HOMA and lower adiponectin are markers of insulin resistance (22,23).
Hispanic women in the US have higher prevalence of elevated insulin and glucose levels,
when compared to non-Hispanic white women (24,25). Specifically, 36.7% of Hispanic
women in the US have elevated fasting plasma glucose levels, compared to 35.7% of nonHispanic white women (25). Additionally, Hispanic women in the US have higher HbA1c
(26), leptin (27), TNF-a (28) and lower adiponectin (29), when compared to non-Hispanic
white women.
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Insulin resistance is an early step towards development of type 2 diabetes (22).
Type 2 diabetes is the seventh leading cause of death in the US and is a risk factor for the
development of cardiovascular disease, the leading cause of death in the US (30). The
prevalence of type 2 diabetes among Hispanic women in the US is almost twice as high as
among non-Hispanic white women (11.6% vs. 6.6%), with 4.9 million Hispanic Americans
having diagnosed diabetes and rates are only increasing (31). Additionally, it is estimated
that an additional 1.5 million Hispanic Americans have undiagnosed diabetes which can
cause potentially severe complications (31,32). Evidence of insulin resistance during
pregnancy and postpartum is associated with the development of gestational diabetes
mellitus (GDM) during pregnancy and type 2 diabetes in the future (33,34).
One of the normal changes that occurs during pregnancy is increased insulin
resistance in the mother to facilitate the transfer of glucose to the fetus (15). However,
some women develop abnormal insulin resistance or GDM during pregnancy which results
in exaggerated insulin resistance and impaired pancreatic function (15). It is well-known
that having GDM is associated with an increased risk of future type 2 diabetes, with nearly
70% of women developing type 2 diabetes after 10 years postpartum (15,35). Women with
GDM, as well as those without GDM but with an abnormal glucose tolerance test, also
experience an increased risk of future cardiovascular disease (8).
Additionally, some insulin resistance biomarkers, such as HbA1c (36) and
adiponectin (18), lower during pregnancy, while others such as leptin (37–39), fetuin-A
(40) and TNF-a (41) increase during pregnancy. However, all insulin resistance biomarkers
typically return to pre-pregnancy levels within 3 months postpartum, and often much
sooner than that (42–45).
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Risk factors for adverse cardiovascular disease and insulin resistance biomarkers
during the pregnancy and postpartum include non-modifiable factors (e.g., family history
or genetics), as well as modifiable risk factors such as smoking, physical inactivity, a diet
of poor quality or excess energy intake, and excess body weight (2,46). Additionally,
women with impaired glucose tolerance during pregnancy or GDM are more likely to have
an adverse postpartum cardiovascular risk and insulin resistance profile, as well as an
increased risk of future type 2 diabetes and CVD (8). Hispanics are particularly susceptible
to these disorders due to lower average socioeconomic status and education levels,
differences in cultural factors, stress related to discrimination and barriers to healthcare
related to language (9).

2. Mechanisms of Lifestyle Behaviors on Pregnancy and Postpartum Cardiovascular
Risk Factors and Insulin Resistance Biomarkers
Participation in regular physical activity or exercise and eating a quality diet have
been associated with improvements in cardiovascular disease risk factors and insulin
resistance profiles in the general adult population. However, the specific cellular
mechanisms between physical activity and diet on cardiovascular risk factors and insulin
resistance are not entirely clear.
Increasing physical activity has been found to lead to improvements in
cardiorespiratory fitness and insulin sensitivity (47). Improved fitness, in turn, has been
associated with: 1) decreases in oxidative stress, inflammation, and sympathetic nervous
system activity, and 2) increases in endothelial function, baroreflex sensitivity, lipoprotein
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lipase activity, hepatic glucose output, secretion of anti-inflammatory cytokines, and
parasympathetic nervous system activity (9,16,47).
Improving diet quality, primarily via a decrease in lipid consumption, has been
shown to improve blood lipid profiles (i.e., decreasing total cholesterol, LDL-C, and
triglycerides, and increasing HDL-C) by decreasing inflammation and altering lipid
pathways (9,16). However, despite acceptance that improved dietary quality, in many
forms, helps to reduce insulin resistance, the mechanisms by which such changes alter
insulin-signaling within relevant tissues is unclear (48,49).

3. Clinical Trials of Lifestyle Interventions on Pregnancy and Postpartum
Cardiovascular Risk Factors and Insulin Resistance Biomarkers
Ten trials have examined the effects of lifestyle interventions on cardiovascular risk
factors and insulin resistance biomarker outcomes in pregnant and postpartum women (50–
59). Among these, two used a quasi-experimental study design (i.e., non-randomized)
(50,56) while the others used randomized controlled trial designs (51–55,57–59). Of these
studies, only one was conducted in the US and among a Hispanic population (57), one
study was conducted in Spain (50), while the rest of the studies were conducted outside of
the US and included either no or a small proportion of Hispanics (51–56,58,59).
Additionally, only one study was performed among women with confirmed GDM (58).
Six of the interventions were implemented within the first 12 months postpartum,
ranging from 4 weeks to 12 months (51,52,56–59), two were initiated during pregnancy
and completed in the postpartum months (54,55), and two were implemented exclusively
during pregnancy (50,53). Among the interventions that only targeted the postpartum
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period, three focused on physical activity only (56,57,59) and three incorporated both
physical activity and diet components (51,52,58). The interventions that began during
pregnancy and continued into the postpartum period both focused on diet only (54,55).
Lastly, the interventions that occurred during pregnancy focused on physical activity only
(50,53).
Among the eight studies that included an exercise component, six involved
supervised exercise training interventions which included one to four sessions per week
with walking groups or at a fitness center, hospital or lab with exercises consisting of light
to vigorous exercise (mostly aerobic) (50,52,53,56,57,59). Of the five studies that included
a dietary component, all provided patient counseling via in person sessions with a dietician
and dietary handouts (51,52,54,55,58). None of the studies used motivational interviewing
within the intervention and only two studies relied upon theoretical models, including
Social Cognitive Theory and Social Support Theory (55,57). Lastly, only three of the ten
trials had a comparison control arm, where women were provided the same contact time
with study personnel (56–58). The additional seven trials used the usual standard of care,
with no control for contact time between study participants and personnel (50–55,59).
Of the five studies that evaluated blood pressure as an outcome, one found a
decrease in overall blood pressure (58), one found an increase in systolic blood pressure
(57), and three were null (51,54,56). Among the studies that evaluated cholesterol as an
outcome, three found a decrease in total cholesterol (51,54,58), four found a decrease in
LDL cholesterol (51,52,54,58), two found an increase in HDL cholesterol (51,58), and five
were null (53,55–57,59). In the five studies that evaluated triglycerides as an outcome, one
found a decrease in triglycerides (58), while five reported null findings (53,55–57,59). In
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the six studies that evaluated insulin as an outcome, four found a decrease in insulin
(51,53,56,58) while two were null (55,57). In the seven studies that evaluated glucose as
an outcome, two found a decrease in glucose (52,58) and five were null (51,53,55–57). In
the two studies that evaluated HbA1c and high-sensitivity C-reactive protein as outcomes,
both reported null findings for both outcomes (53,55). In the three studies that evaluated
HOMA as an outcome, all three found a decrease in HOMA (53,56,58). The one study that
evaluated adiponectin as an outcome, found an increase in adiponectin (52). Additionally,
the one study that evaluated TNF-a as an outcome, found a decrease in TNF-a (50). There
are no prior studies that have evaluated fetuin-A, the albumin-to-creatinine ratio, nor leptin
as outcomes.
Overall, the three prior studies that incorporated both physical activity and dietary
interventions reported greater changes in cardiovascular risk factors and insulin resistance
biomarkers as compared to those studies whose interventions targeted physical activity or
diet alone.
In the only study to date that was performed among Hispanic women in the US,
Vega-Lopez et al. performed a 2-arm randomized controlled trial among 44 postpartum
Hispanic women (57). Women who were randomized into the intervention arm participated
in a postpartum walking intervention of moderate intensity with weekly walking groups,
support sessions and follow-up phone calls from study personnel for 12 months, while
women in the control arm were provided weekly newsletters with unrelated information
and follow-up calls (57). This study was developed with the Social Support theoretical
framework (57). When comparing the intervention arm to the control arm, systolic blood
pressure significantly increased by 8.0 mmHg (p=0.002) but there were no observed,
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statistically significant differences between the arms with regards to diastolic blood
pressure, total cholesterol, HDL and LDL cholesterol, triglycerides, insulin nor glucose
(57). However, this study was conducted in a small population of women (n=44), which
likely limited the power of the study to be able to detect any differences, if present.
Additionally, this study provided a physical activity only intervention which has been
shown to have a lesser effect on cardiovascular risk factors and insulin resistance
biomarkers than interventions that incorporate both physical activity and dietary
recommendations (60–62). Lastly, although Vega-Lopez et al. utilized the social support
theoretical framework, their study recruitment and methods were not culturally tailored to
Hispanic women (i.e., provided study materials in Spanish and tailor physical activity
recommendations to cultural values, attitudes, beliefs and norms).
In summary, the prior epidemiologic studies of lifestyle interventions and
cardiovascular risk and insulin resistance biomarkers have several gaps and limitations: 1)
the vast majority were performed outside of the U.S. or in non-Hispanic populations, who
are at lower risk of type 2 diabetes, 2) only three out of nine of the studies incorporated
both physical activity and dietary interventions, 3) the majority had physical activity and/or
dietary interventions that required participants to go to a location, making them less
accessible and more cost-prohibitive than at-home interventions, and 4) the majority were
performed among relatively small samples of individuals, raising concerns about the power
of such studies to detect differences. Therefore, we evaluated the effect of a physical
activity and dietary intervention on cardiovascular risk and insulin resistance biomarkers
among approximately 100 Hispanic women in Massachusetts during late pregnancy
through one year postpartum. The lifestyle intervention is culturally modified,
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motivationally targeted, and individually tailored to Hispanic women in the U.S. and was
provided to women primarily through mail-based intervention materials and telephone
counseling sessions, reducing the burden on participants and the cost of delivery.

4. Summary of Significance and Innovation
The American Heart Association posits that to successfully reduce cardiovascular
disease risk approaches should be individually tailored and provide prevention and
treatment at the individual level (5). Therefore, we propose to evaluate the effect of a
culturally modified, motivationally targeted and individually tailored lifestyle intervention
on cardiovascular risk and insulin resistance biomarkers among Hispanic women with a
history of abnormal glucose tolerance in pregnancy. This study is significant in that it
targets an ethnic group that has high rates of modifiable risk factors for cardiovascular
disease (e.g., physical inactivity, impaired glucose or diabetes, and obesity) by intervening
during both the prenatal and postpartum periods. Additionally, this approach is innovative
due to its utilization of a theory-based, individualized lifestyle intervention in a minority
population that includes novel materials to target cardiovascular risk factors and insulin
resistance biomarkers and would be readily translatable into clinical practice in this highrisk population at a low cost.

B. Specific Aims and Hypotheses
Specific Aim #1: Evaluate the impact of a lifestyle intervention on pregnancy and
postpartum biomarkers of cardiovascular risk among Hispanic women with a history of
abnormal glucose tolerance in pregnancy.

10

Hypothesis #1: Participants randomized to the LI arm will have lower total
cholesterol, LDL cholesterol, triglyceride concentrations, systolic and diastolic
blood pressure, C-reactive protein (CRP), fetuin-A and albumin-to-creatinine ratio
(ACR) and higher HDL cholesterol, compared to participants randomized to the
comparison HW arm.

Specific Aim #2: Evaluate the impact of a lifestyle intervention on pregnancy and
postpartum biomarkers of insulin resistance among Hispanic women with a history of
abnormal glucose tolerance in pregnancy.
Hypothesis #2: Participants randomized to the LI arm will have lower fasting
concentrations of glucose, insulin, HbA1c, leptin, TNF-alpha, lower homeostasis
model assessment (HOMA) and higher concentrations of adiponectin as
compared to participants randomized to the comparison HW arm.

C. Study Design and Methods
1. Study Design
Estudió PARTO (Project Aiming to Reduce Type twO diabetes). Estudió PARTO
was a randomized controlled trial designed to test the efficacy of a culturally and
linguistically modified, individually tailored lifestyle intervention to reduce risk factors
for type 2 diabetes and cardiovascular disease, including postpartum cardiovascular risk
and insulin resistance biomarkers. Eligible women were recruited at the time of routine
screening for gestational diabetes mellitus (GDM) (i.e., 24 to 28 weeks of pregnancy) and
randomly assigned to either the LI arm (intervention arm) or the HW arm (control arm)

11

(Figure 1). Randomization was stratified based on oral glucose tolerance test levels. The
intervention began with an Introductory Phase (~29 weeks of gestation) followed by an
Active Phase (~6 weeks to 6 months postpartum and a Maintenance Phase (~6 to 12
months postpartum). At enrollment during pregnancy, a fasting blood sample was
collected and will serve as the baseline measure for biomarkers measured at that point
(i.e., total, LDL and HDL cholesterol, triglycerides, insulin, glucose, HbA1c, and
HOMA). During the postpartum period, fasting postnatal samples were collected at 6
weeks, 6 months and 12 months postpartum via home visits by study assessors; 6 weeks
postpartum will serve as the baseline for those biomarkers not assessed during pregnancy
(i.e., systolic and diastolic blood pressure, CRP, fetuin-A, ACR, adiponectin, leptin, and
TNF-a). All protocols were approved by the Institutional Review Boards at the
University of Massachusetts Amherst and Baystate Health.

2. Study Population
Estudió PARTO took place at the ambulatory obstetrical practices of Baystate
Medical Center located in Western Massachusetts. Inclusion criteria included pregnant
Hispanic women between 24 to 28 weeks of gestation who had an abnormal result (i.e.,
>= 135 mg/dL) on the GDM screening test (n=204). Participants were excluded if they:
1) had a history of type 1 or type 2 diabetes, heart disease, or chronic renal disease, 2)
had contraindications to intervention activities (i.e., physical activity and diet
modification) during the postpartum period, 3) were unable to read English or Spanish at
a 6th grade level, or 4) were under 18 years of age or over 45 years of age at the time of
recruitment. Of those enrolled in the study, 104 chose not to participate in the study after
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delivery, and thus were excluded due to missing biomarker data at pregnancy and/or all
three postpartum time points. Therefore, the final sample included 100 women: LI (n=45)
and HW (n=55).

3. Intervention
The LI incorporated materials developed in previous trials in Hispanic
populations (63–66) as well as theoretical concepts and strategies from Social Cognitive
Theory (67) and Transtheoretical Model (68).
The Introductory Phase (from ~29 weeks of gestation through the time of
delivery) began with a face-to-face session, where the goal was to maintain optimal
gestational weight gain for the remainder of the pregnancy period, as well as to shift from
the pre-contemplation stage to the contemplation stage via targeting knowledge and
attitudes about postpartum weight loss and type 2 diabetes prevention. Tailoring
questionnaires - including an Exercise Tailoring Questionnaire, The Dietary Self-Efficacy
Scale, the Latino Dietary Behaviors Questionnaire and an individualized Dietary Target
Goals Assessment Checklist – were administered at this time to facilitate individualized
interventions throughout the remainder of the study. Motivational interviewing was used
to identify and strengthen participants’ motivations for change. A telephone counseling
session served as a booster session to review progress with gestational weight gain
management and reinforced the plan for the postpartum period. Print-based intervention
materials were also mailed in either English or Spanish, dependent on participant
preference.
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Second, the Active Phase (~6 weeks to 6 months postpartum) also began with a
face-to-face session that focused on the development of plans for postpartum weight loss,
achieving ACOG guidelines for postpartum physical activity, and reducing postpartum
total caloric intake as recommended by the American Diabetes Association (69,70). This
session was followed by weekly, biweekly, and monthly print-based materials, including
the tailoring questionnaires, and telephone booster calls that were individually tailored
and incorporated progress review, problem-solving discussion, and goal setting
assistance.
Finally, the Maintenance Phase (6 to 12 months postpartum) continued with
telephone counseling sessions and mailed materials, first monthly, and then bimonthly.

4. Comparison
The comparison arm received the HW intervention which included face-to-face
visits, mailed health materials and telephone booster calls on the same schedule as the LI
participants. However, the self-help materials focused on non-exercise and non-dietary
topics, so the content remained distinct from that provided to the LI arm.

5. Outcome Variables: Pregnancy and Postpartum Cardiovascular Risk and Insulin
Resistance Measures
Biomarkers of cardiovascular risk will include systolic and diastolic blood
pressure, blood lipids (i.e., total cholesterol, LDL cholesterol, HDL cholesterol, and
triglycerides), CRP, fetuin-A and ACR. Biomarkers of insulin resistance will include
insulin, glucose and HbA1c, leptin, TNF-𝛼, adiponectin and HOMA.
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Blood pressure was measured at enrollment in late pregnancy and the postpartum
assessment visits with an automated Omron Blood Pressure Monitor with the cuff placed
on the upper arm over the brachial artery. The Omron Blood Pressure Monitors have
been validated to assess blood pressure within an error range of 3 mmHg (or 2%), which
is within the Association of Medical Instrumentation standards. Systolic and diastolic
blood pressure readings were reported as continuous variables.
Blood lipids were measured using the Roche P Modular system at enrollment in
late pregnancy and the postpartum assessment visits. Total cholesterol was measured
using enzymatical methods (71). Day-to-day reproducibility have been reported as 1.7%
(SD = 2.4 mg/dL) and 1.6% for cholesterol concentrations of 132.8 and 280.4 mg/dL,
respectively (71). A homogenous direct method was used to determine LDL cholesterol
(72). Day-to-day variabilities of LDL cholesterol with this method have been reported as
3.01, 2.34, and 2.18% for concentrations of 90, 160, and 12 mg/dl, respectively. A direct
enzymatic colorimetric assay was used to determine HDL cholesterol (73). The day-today reproducibility for HDL cholesterol concentrations of 27.0 and 54.9 mg/dL were
reported as 3.3% (SD = 0.9) and 1.7% (SD = 0.9), respectively. Triglycerides were also
measured enzymatically, but with a correction for endogenous glycerol (74). Day-to-day
reproducibility of 1.8% (SD = 1.6) and 1.7% (SD = 3.5) were reported for concentrations
of 84.0 and 201.8 gm/dL, respectively. All blood lipid data were analyzed as continuous
variables.
High sensitivity CRP was measured at the postpartum assessment visits on the
Roche P Modular system with an immunoturbidimetric assay with reagents and
calibrators from DiaSorin (Stillwater, MN). CRP concentrations of 0.91, 3.07, and 13.38
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mg/L have reported day-to-day variabilities of the assay of 2.81, 1.61, and 1.1%,
respectively. CRP was analyzed as a continuous variable.
Fetuin-A was measured at the postpartum assessment visits using an enzyme
immunoassay (EIA) (BioVendor – Candler, NC). The assay possesses a sensitivity of
0.35 ng/mL and a run-to-run imprecision at concentrations of 12.8 and 27.2 ng/mL of
5.1% and 2.6%, respectively.
ACR will be calculated as (albumin concentration/creatinine concentration).
Albumin and creatinine were measured at the postpartum assessment visits. Albumin was
measured using a colorimetric assay, an automated dye-binding method using the Roche
P Modular System and Roche Diagnostic reagents (Indianapolis, IN). The day-to-day
variabilities at concentrations of 2.48 and 3.87 g/dL have been reported as 2.75% and
1.91%, respectively. Creatinine was measured by an enzymatic method using the Roche
P Modular System and Roche Diagnostics reagents (Indianapolis, IN). Creatinine at
concentrations of 1.54, 1.61 and 3.69 mg/dL have a reported day-to-day variability of
2.1%, 1.6% and 2.5%, respectively.
Insulin, glucose and HbA1c were measured at enrollment in late pregnancy and
the postpartum assessment visits. Fasting insulin (FI) was measured by an
electrochemiluminescence immunoassay on the Roche E Modular system. The lowest
detection limit of this assay is 0.2 uU/mL and the day-to-day imprecision values at
concentrations of 6.36, 20.9 and 747 uU/mL have been reported as 2.6%, 2.8% and 2.5%,
respectively. Fasting glucose (FG) was measured enzymatically on the Roche P Modular
system using Roche Diagnostics reagents (75). Day-to-day variability of glucose
concentrations of 90 and 312 mg/dL have been reported as 1.7% and 1.6%, respectively.
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HbA1c determination on the Roche R Modular system was based on turbidimetric
immunoinhibition using packed red cells. The day-to-day variability at values of 5.5 and
9.1 have been reported as 1.9% and 3.0%, respectively.
Leptin was measured at the postpartum assessment visits using an ultra-sensitive
ELISA assay, an enzymatically amplified “two-step” sandwich-type immunoassay (R&D
Systems, Minneapolis, MN). The day-to-day variability at concentrations of 65.7, 146
and 581 pg/mL has been reported as 5.4%, 4.2% and 3.5%, respectively.
TNF-𝛼-receptor II, herein referred to as TNF-𝛼, was measured at the postpartum
assessment visits using an ELISA assay from R&D Systems that employs the quantitative
sandwich enzyme immunoassay technique. The day-to-day variabilities of the assay at
concentrations of 89.9, 197 and 444 pg/mL are 5.1%, 3.5% and 3.6%, respectively.
Adiponectin was measured at the postpartum assessment visits using an ELISA
method from ALPCO Diagnostics Inc. (Salem, NH). The day-to-day variability at 9130
and 3930 have been reported as 9.8% and 10.2%, respectively.
HOMA will be calculated as [(FI x FG)/22.5] on a scale of 1 to 8.

6. Covariate Measures
Medical history variables included pre-pregnancy body mass index (BMI), family
history of diabetes, and parity and were extracted from medical records at study
enrollment. Pre-pregnancy BMI will be presented continuously, while family history of
diabetes and parity will be presented categorically.
Clinical characteristics of the current pregnancy included gestational weight gain,
glucose tolerance, and confirmed diagnoses of hypertension or preeclampsia. Glucose
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tolerance, gestational weight gain, and confirmed diagnoses of hypertension or
preeclampsia were obtained from medical records. Maternal weight in kg was assessed at
each medical visit during pregnancy. Gestational weight gain was determined as the
difference between maternal weight at delivery and pre-pregnancy weight and will be
categorized as below, within, or above the 2009 Institute of Medicine gestational weight
gain guidelines (76). Glucose tolerance test results were also extracted from medical
records and will be categorized as normal, isolated hyperglycemia, impaired glucose
tolerance, or gestational diabetes mellitus (77).
Pre-pregnancy smoking, smoking during pregnancy, and alcohol use during
pregnancy were self-reported at study enrollment and throughout pregnancy using the
Pregnancy Risk Assessment Monitoring System and will be categorized as yes or no
responses (78). Depression was measured using the Edinburgh Postpartum Depression
Scale during the postpartum period. At least probable minor depression will be defined as
having a score of at least 13 on that scale and will be dichotomized as yes or no. Sleep
was measured using the Pittsburgh Sleep Quality Index (PSQI) during the postpartum
period. The total sleep score will be derived from the PSQI and will be presented
continuously with a lower score representing better sleep. The type of feeding for the
infant (i.e., breastfeeding, formula or both) will be derived from a modified version of the
validated Infant Feeding Questionnaire (79).
Sociodemographic measures were collected from self-report at study enrollment
and included age, education, annual household income, marital status, generation in the
U.S., acculturation status, living with spouse or partner, number of adults living in the
same household (18 years or older), and number of children living in the household
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(under 18 years). Acculturation status was measured using the Psychological
Acculturation Scale (80) and will be categorized as low acculturation (scoring 1 to less
than 3 on the scale) or high acculturation (greater than 3 on the scale).

D. Data Analysis
Specific Aim #1: Evaluate the impact of a lifestyle intervention on pregnancy and
postpartum biomarkers of cardiovascular risk among Hispanic women with a history of
abnormal glucose tolerance in pregnancy.

Specific Aim #2: Evaluate the impact of a lifestyle intervention on pregnancy and
postpartum biomarkers of insulin resistance among Hispanic women with a history of
abnormal glucose tolerance in pregnancy.

1. Univariate Analyses
The number and percentage of participants who were recruited and were excluded
are presented (Figure 1). We also assessed the means and standard deviations of the
cardiovascular risk and insulin resistance biomarker outcome variables at late pregnancy
baseline (~29 weeks gestation) and 6 weeks postpartum baseline.

2. Bivariate Analyses
We used two-sample t-tests and chi square tests to determine if the intervention
arms had different distributions of covariates at baseline (i.e., late pregnancy or 6 weeks
postpartum) (Table 1.2a & 1.2b).
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3. Multivariate Analyses
An intent to treat analysis was used to evaluate differences in the changes of
cardiovascular disease risk factors and insulin resistance biomarkers between the
intervention arms from baselinepreg (late pregnancy) to 6 weeks postpartum, 6 months
postpartum and 12 months postpartum. For those biomarkers assessed only in the
postpartum period, we evaluated differences in change from 6 weeks postpartum
(baselinepost to 6 and 12 months postpartum). Within arm differences in mean changes
and mean percent changes from both baselines to each follow-up time point were
assessed with two-sample t-tests among both treatment arms (Table 1.3a, 1.3b, 1.4a, &
1.4b). Differences in change in each cardiovascular risk and insulin resistance biomarker
outcome variable were assessed with a mixed effect model with random subject effects,
including a common mean at baseline for the treatment arms (groups), a time effect, and
a group by time interaction (Table 1.3a, 1.3b, 1.4a, & 1.4b)(81). Specifically, mixed
models were used to evaluate differences in the change in cardiovascular risk and insulin
resistance biomarkers from baseline to 12 months postpartum between the intervention
arms. These models will account for the repeated measures of cardiovascular risk and
insulin resistance biomarkers with random subject effects and incorporated fixed
assessment time effects using baseline cardiovascular risk and insulin resistance
biomarkers as the reference.
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4. Sensitivity Analyses
We performed several sensitivity analyses. First, we conducted two-sample t-tests
and chi-square tests to evaluate whether the final analysis group has different
distributions of covariates at baseline as compared to those who were excluded from the
analysis due to missing data (Table 1.5). Second, we limited the analysis to women in the
LI arm who were compliant with the intervention defined as: 1) meeting the ACOG
exercise guidelines and 2) returning >1 tailoring questionnaires during the postpartum
period to evaluate whether receiving the planned dose of the intervention affects
differences in cardiovascular risk and insulin resistance biomarkers between the
intervention arms (Table 1.6a & 1.6b). Additionally, we will limit the sample to women
who had an overweight or obese pre-pregnancy BMI as there is evidence that lifestyle
interventions may be more effective among this group (Table 1.7a & 1.7b) (82). We also
assessed whether type and intensity of self-reported physical activity, regardless of the
assigned intervention arm is associated with change in cardiovascular risk and insulin
resistance biomarkers (Table 1.8a-1.8p). Lastly, we assessed whether participants who
were adherent to ACOG guidelines of physical activity, regardless of the assigned
intervention arm, had different distributions of covariates at baseline as compared to
those who were non-adherent to ACOG guidelines of physical activity (Table 1.9).

E. Results
The final analytic sample included 61 participants in the LI arm and 70
participants in the HW arm. Participants in the LI and HW arms were largely comparable
according to covariates, however participants in the LI arm had lower rates of IHG and
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higher rates of IGT compared to participants in the HW arm (32.79% vs. 55.71% and
31.15% vs. 7.14%, p<0.05, respectively) (Table 1.1). Additionally, participants in the LI
arm had lower rates of confirmed preeclampsia compared to participants in the HW arm
(0% vs. 9.38%, p=0.03) (Table 1.1).
We then evaluated the within arm change in biomarkers from baseline through 6
weeks, 6 months, and 12 months postpartum (Table 1.2a and 1.2b). When using late
pregnancy as the baseline, in both the LI and HW arms, all cardiovascular disease risk
biomarkers (i.e., cholesterol, LDL, HDL, and triglycerides), glucose, and HbA1c
significantly decreased from late pregnancy through 6 weeks, 6 months, and 12 months
postpartum (Table 1.2a). Among the LI arm only, there was a significant -5.33uIU/mL
decrease in insulin from late pregnancy to early postpartum (Table 1.2a). We then
evaluated the within-arm change in biomarkers using 6 weeks postpartum as the baseline.
In both the LI and HW arms, ACR significantly increased from 6 weeks to postpartum
(LI: 0.39, HW: 0.30). However, among the LI arm, there was a significant -51.28ng/mL
decrease in fetuin-A and -5.68pg/mL in leptin through postpartum (Table 1.2b), while
among the HW arm only, there was a significant -202.30pg/mL decrease in TNF-a
through postpartum (Table 1.2b).
Next, we evaluated the differences in mean change from baseline to follow-up
between the intervention arms using both pregnancy (Table 1.3a) and postpartum (Table
1.3b) as baseline. The majority of cardiovascular risk and insulin resistance biomarkers
showed no difference in mean change between the intervention arms. However, there was
a statistically significant 4.31mg/dL mean difference in decrease in HDL cholesterol
between arms (Table 1.3a) with the LI arm experiencing a greater decrease in HDL
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cholesterol concentration across all time points (beta=-4.31, 95% CI: -8.35, -0.28).
Additionally, the intervention by time interaction was statistically significant for TNF-a
indicating that the advantage of the LI relative to the HW intervention was different at 6
months compared to 12 months postpartum. Specifically, there was a statistically
significant difference in change in TNF-a between arms from late pregnancy through 12
months postpartum (Table 1.3b) with the LI arm experiencing a greater increase in TNF-a
concentration (p=0.03).
We then evaluated the differences in mean percent change from baseline to
follow-up between the intervention arms using both pregnancy (Table 1.4a) and
postpartum (Table 1.4b) as baseline. Again, we observed no differences in mean percent
change between the LI and HW groups for the majority of the cardiovascular risk and
insulin resistance biomarkers. However, similar to the absolute change results described
above, there was a statistically significant difference in percent HDL cholesterol change
between arms (Table 1.4a), with the LI arm experiencing a greater decrease in HDL
cholesterol from late pregnancy to 12 months postpartum (beta=-7.58mg/dl, 95% CI: 14.21, -0.94). There was also a statistically significant difference in percent insulin
change between the study arms from late pregnancy to 12 months postpartum (beta=17.23uIU/mL, 95% CI: -33.72, -0.74) (Table 1.4a) with the LI arm experiencing a greater
decrease in insulin. Lastly, and again similarly to the absolute change results described
above, there was a statistically significant difference in percent change in TNF-a from 6
weeks postpartum to 12 months postpartum, with the LI arm experiencing a greater
increase in TNF-a concentration (mean=9.92, p=0.03) (Table 1.4b). All multivariate
analyses were adjusted for impaired glucose tolerance and confirmed preeclampsia, due
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to differences among the intervention arms at baseline, however results did not vary so
unadjusted results are presented.
We then conducted several sensitivity analyses. First, we evaluated whether there
were differences in the distribution of covariates and baseline biomarkers between those
women who were lost to follow-up compared to those who were not (Table 1.5). Women
who were lost to follow-up did not differ from those not lost according to covariates but
did have lower CRP at 6 weeks postpartum (3.86 vs. 5.49mg/L, p=0.03) (Table 1.5).
Secondly, we evaluated whether findings differed according to adherence with the
intervention as defined as compliance with the ACOG guidelines or the return of the
PATQ tailoring questionnaires using both pregnancy (44.26% and 75.44%, respectively),
(Table 1.6a) and postpartum (55.56% and 93.33%, respectively) (Table 1.6b) as baseline.
In this per protocol analysis, there were no differences among most cardiovascular risk
and insulin resistance biomarkers, according to adherence with the intervention. When
we limited the analysis to those in the LI arm who were adherent with the intervention,
differences in change in HDL cholesterol and insulin between the arms from late
pregnancy through 12 months postpartum were attenuated (Table 1.6a). However, there
were significant differences in change in TNF-a among those who were adherent in the
LI arm compared to the HW arm (ACOG: 251.72pg/mL, p=0.047; PATQ: 205.31pg/mL,
p=0.03) (Table 1.6b). When comparing the characteristics of those who were adherent to
AGOG guidelines, compared to those who were nonadherent, we observed no differences
in the distribution of covariates across the groups (results not shown).
Third, we evaluated whether the effect of the intervention would differ among
women who had an overweight or obese pre-pregnancy weight using pregnancy (Table
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1.7a) and postpartum (Table 1.7b) as baseline. Findings for HDL cholesterol were
virtually unchanged while the remaining findings were attenuated or remained null
(Tables 1.7a & 1.7b).
Lastly, we evaluated whether different intensities and types of physical activity,
as opposed to assigned intervention arm, affected the cardiovascular risk and insulin
resistance biomarkers (Tables 1.8a-1.8p). We observed no differences in change in
triglycerides, insulin, HbA1c, HOMA, nor adiponectin across intensities and types of
physical activity (Tables 1.8d, 1.8j, 1.8l-8n). However, we found statistically significant
differences in change in cholesterol, LDL, HDL, systolic and diastolic blood pressure,
CRP, ACR, glucose, leptin, TNF-a, and fetuin-A across intensities and types of physical
activity (Tables 1.8a-1.8c, 1.8e-1.8i, 1.8k, 1.8o, 1.8p). Participation in occupational and
sports/exercise activity above the median and meeting the ACOG guidelines were
associated with significant differences in change in CVD biomarkers (Tables 1.8a-1.8g,
1.8i), while participation in moderate, combined moderate-vigorous, and sports/exercise
activity above the median were associated with significant differences in insulin
resistance biomarkers (Tables 1.8h, 1.8k, 1.8o, 1.8p).

F. Discussion
In this randomized controlled trial among Hispanic women with abnormal glucose
tolerance during pregnancy, we found that a culturally modified, individually tailored
lifestyle intervention did not lead to a significant difference in change over postpartum
follow-up time in the majority of cardiovascular disease risk and insulin resistance
biomarkers. However, we observed significantly lower insulin concentrations and lower
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HDL among the LI arm compared to the comparison HW arm over the course of late
pregnancy through 12 months postpartum. Additionally, we observed a significantly
lower TNF-a concentrations among the LI arm compared to the comparison HW arm
from 6 weeks through 12 months postpartum. We also observed that women who
participated in sports or exercise physical activity during postpartum – regardless of their
assigned intervention arm – had significantly improved levels of several cardiovascular
disease risk and insulin resistance biomarkers, including cholesterol, diastolic blood
pressure, and glucose.
Our findings of a statistically significance decrease in insulin between the LI arm,
compared to the HW arm, are consistent with some (51,53,56,58) but not all prior studies
(55,57). Similar to our study, Zilberman-Kravits et al. was the only prior study to recruit
women who had abnormal glucose tolerance (i.e., GDM) during pregnancy, however,
women were recruited at 3-4 months postpartum compared to the current study which
recruited when during late pregnancy (58). These participants attended individual and
group counseling sessions in Israel through 2 years postpartum (58). The authors found a
statistically significant decrease in insulin (-5.1 uIU/mL), glucose (-11.2 mg%), and
HOMA (-1.5) among women in the lifestyle intervention compared to a usual care group
(58). Additionally, trials conducted among women based in Sweden, Norway, and the
Netherlands, found significant decreases in insulin, from -0.3 to -5.9 uIU/mL, among the
intervention arm, compared to the usual care group over the course of 12 weeks
postpartum (51,56) or 18-24 weeks gestation (53). In the current study, we observed a
decrease in insulin of -4.5 uIU/mL. In contrast, Martin et al. (-1.9 uIU/L) and Vega Lopez
et al. (-8.9 uIU/mL) found no statistically significant difference in insulin between arms
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over 6 and 12 months postpartum, respectively (55,57). Differences between the current
study and that by Martin et al. and Vega Lopez et al. may be due to differences in study
methods. For example, neither study was conducted among women with abnormal
glucose tolerance during pregnancy and Martin et al. was conducted outside of the US
and among non-Hispanic women (55,57). Additionally, Martin et al. used only a dietary
intervention, while Vega-Lopez et al. used only a physical activity intervention (55,57).
The current study had a combined dietary and physical activity intervention, which has
been recognized to have a stronger effect than either behavioral change element alone.
Our observation of a statistically significant difference in TNF-α between the
intervention arms, with the LI arm having significantly lower TNF-α concentrations (i.e.,
-52.5 pg/mL) than the HW arm is consistent with the only prior study to evaluate this
association (50). However, the prior study observed a smaller difference in change
between the intervention arms (-0.7 pg/mL) with the intervention experiencing a lower
TNF-α concentration (50). Both the current and prior study utilized a physical activity
intervention, however the current study included women who were at high-risk for type 2
diabetes, provided a longer duration intervention through postpartum, and included
dietary modification as part of the intervention. TNF-a is an inflammatory cytokine with
elevated TNF-a acting as a mediator that contributes to the development of insulin
resistance and subsequent type 2 diabetes (22,23,83). Hispanic women in the US have
higher TNF-a concentrations, when compared to non-Hispanic white women, making
evaluation of this novel biomarker especially important among this high-risk population
(28).
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Our findings of an adverse impact of the lifestyle intervention on HDL cholesterol
is inconsistent with prior literature that either observed a significant increase in HDL
cholesterol among the intervention arm (51,58) or no difference in HDL cholesterol
between the intervention arms (53,55–57,59). Specifically, we observed that the LI arm
had a 4.3 mg/dL lower HDL as compared to the HW arm, however both arms were still
below the desired HDL range (i.e., 60 mg/dL). It is reassuring, however, that we did not
observe similar corresponding negative impact on total cholesterol and LDL cholesterol.
Lastly, HDL cholesterol is largely impacted by obesity, lack of exercise and good diet,
smoking, and alcohol consumption (84). We observed that this decrease in HDL
cholesterol was attenuated when we limited the study sample to include only those
participants who were compliant to the ACOG guidelines (LI arm: 44%, HW arm: 61%).
Therefore, it is more likely this observation is due to chance given the multiple
comparisons performed.
While we did not observe an impact of the intervention on LDL and total
cholesterol, four of the prior studies found that a lifestyle intervention led to a statistically
significant decrease in LDL ranging from 1.8 mg/dL to 36.2 mg/dL (51,52,54,58), while
three of the prior studies found that a lifestyle intervention led to a statistically significant
decrease in total cholesterol ranging from 3.6 mg/dL to 30.5 mg/dL (51,54,58). We also
did not observe an impact on HOMA while all three of the prior studies that evaluated
this measure found improvements in HOMA ranging from 1.2 to 1.5 (53,56,58).
Overall differences between the current study and these prior studies are likely
due to differences in study methods. For example, only one of the prior ten studies was
conducted in the United States (57), with all other prior studies having populations from
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northern Europe, Spain, Greece, Canada, Australia, and Israel (50–56,58,59). More
importantly, only one study was conducted among women with abnormal glucose
tolerance during pregnancy (58). Women who develop abnormal glucose tolerance
during pregnancy are already at an increased risk for the development of cardiovascular
disease and type 2 diabetes, compared to women with normal glucose tolerance during
pregnancy. Therefore, a more intensive or higher dose intervention may be needed to
improve biomarkers of cardiovascular disease in this group. For example, prior studies
largely used supervised (50,52,53,56,58) or group physical activity and/or dietary
sessions (54,58). In contrast, the current study encouraged women to meet ACOG
guidelines for physical activity at home (i.e., unsupervised). ACOG guidelines may be
too modest to impact cardiovascular disease risk and insulin resistance biomarkers among
this high-risk group. In addition, compliance with the lifestyle intervention was low over
the postpartum period (44%). Finally, the two studies with the longest active intervention
periods (i.e., 19-20 months during gestation and postpartum or postpartum alone) saw
consistently beneficial impacts of the intervention on cardiovascular and/or insulin
resistance biomarkers (54,58). In contrast, the current study had a 12-month active
intervention (from early pregnancy to 6 months postpartum).
Our findings of a beneficial impact of above the median levels of sports and
exercise physical activity during late pregnancy and postpartum – regardless of
intervention arm - on several cardiovascular disease risk and insulin resistance
biomarkers, is consistent with prior literature (85,86). This suggests that in our study
population, if the lifestyle intervention could lead to the performance of above the median
sports and exercise physical activity, then it would likely have a positive impact on
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cardiovascular disease and insulin resistance risk in this study population during the
postpartum period.
This study has several limitations. First, non-differential misclassification of the assigned
intervention arm could have occurred in this study in the per protocol analysis.
Participants who had been randomized to the LI arm could have performed little physical
activity and dietary modifications, while participants who had been randomized to the
HW arm could have performed recommended levels of physical activity and dietary
modifications. This is likely to have occurred, given that not all participants randomized
to the LI arm will follow the provided recommendations and intervention, while
participants randomized to the HW arm may change their habits regardless of the study or
due to the social supports provided. Specifically, we observed that 56% of the LI arm did
not meet the ACOG guidelines at any time postpartum, while 39% of the HW arm did.
However, we observed no differences in the distribution of covariates among those who
were ACOG compliant compared to those who were not. Additionally, this study’s
utilization of a control arm matched for contact time minimizes the concern that social
support alone led to any observed changes, as opposed to changes being due to the
lifestyle content of the intervention. Finally, to the extent that non-differential
misclassification of the assigned intervention arm occurred, it would bias the results from
the intent-to-treat results towards the null. However, our allocation system, utilized by the
health educators and assessors, makes this concern highly unlikely (63).
Additionally, non-differential misclassification of the cardiovascular risk and
insulin resistance biomarkers could have occurred due to laboratory error, if the
biomarkers of interest had substantial variability, or if they did not reflect what was
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intended to be measured. For example, if blood pressure measures had large withinperson variability or if they reflected only short vs. long-term levels then there could be
non-differential misclassification of blood pressure. If non-differential misclassification
of the cardiovascular risk and insulin resistance biomarkers had occurred it would bias
the results towards the null; however, this concern is reduced given the low coefficients
of variation for the biomarkers of interest, the use of best practices in biomarker
measures, and the likelihood of the effect being non-differential between the intervention
arms.
Despite the substantial loss to follow-up in the study (51%), differential loss to
follow-up is unlikely to have occurred since we observed similar loss to follow-up for
both randomization arms (LI: 55%, HW: 48%). This, in combination with the comparable
distribution of covariates among those who were included in the analysis group and those
who were missing all biomarker measures, minimizes the concern about differential loss
to follow-up.
Information bias, where information on the biomarkers of interest were obtained
differently between the two treatment arms, or where one arm was followed more closely
than the other, is unlikely to have occurred in this study. The methods for obtaining and
analyzing the cardiovascular risk and insulin resistance biomarkers were the same for
both treatment arms and assessors of the biomarkers of interest were blinded to the
treatment arm of participants.
Confounding is unlikely to have affected this study due to the use of
randomization. When comparing the distribution of covariates between the intervention
arms, we observed differences in the distributions of glucose tolerance and confirmed
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diagnosis of preeclampsia across the intervention arms. However, upon inclusion of these
two covariates in multivariate models, results did not vary. However, it is possible that
randomization did not result in the comparable distribution of unknown covariates and
therefore, residual confounding could remain.
Lastly, due to the cultural tailoring of the provided intervention and the restriction
of the study population to Hispanic women with abnormal glucose tolerance during
pregnancy, the results of this study should be limited to other Hispanic postpartum
women with an abnormal glucose tolerance during pregnancy.
There is biological evidence that participation in physical activity and consuming
a quality diet may contribute to advantageous changes in CVD and insulin resistance
biomarkers via decreases in oxidative stress, inflammation, sympathetic nervous system
activity, altered lipid pathways, and secretion of anti-inflammatory cytokines (9,16,47).
When evaluating insulin resistance biomarkers, we observed that a lifestyle intervention
of physical activity and dietary modifications was associated with clinically and
statistically significant decreases in insulin of -4.52 uIU/mL, with the LI arm having a
reduction in blood insulin levels from late pregnancy through 12 months postpartum.
Blood insulin concentrations in the LI arm were within recommended blood insulin
concentrations while the HW arm had blood insulin levels that remained elevated above
recommended values at 12 months postpartum.
Additionally, we observed that a lifestyle intervention was associated with a
significant decrease in TNF-a concentrations from 6 weeks through 12 months
postpartum among the LI arm compared to the HW arm. TNF-a is an inflammatory
cytokine that promotes insulin resistance via inflammatory signaling (87). The observed
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reduction in TNF-a among the LI arm of 30 to 131 pg/mL could be caused by the
decreases in inflammation associated with performing physical activity and incorporating
a quality diet (9,16). However, the observed TNF-a concentrations remain above the
recommended levels among both the LI and HW arms (88).
Lastly, among CVD biomarkers, we observed an adverse decrease in HDL
cholesterol among the LI arm, compared to the HW arm, from late pregnancy through 12
months postpartum. This adverse decrease in HDL cholesterol ranging from 3.58 to 6.02
mg/dL is not considered to be clinically significant as HDL cholesterol levels remained
clinically elevated in both the LI and HW arms (89). In addition, this decrease was not
accompanied by associated adverse changes in total cholesterol nor LDL cholesterol and
was not observed among those who were adherent to the physical activity and dietary
intervention. These factors minimize concern that this association reflects a true
biological change in HDL cholesterol and instead suggest that this association is likely
attributable to those participants who were not compliant to the assigned physical activity
and dietary intervention who continue to be at high-risk for adverse lipid profiles.
In summary, in this randomized controlled trial of a culturally tailored,
individually modified lifestyle intervention among Hispanic women with abnormal
glucose tolerance during pregnancy, we observed a significant difference in insulin, HDL
cholesterol, and TNF-a concentrations between the intervention arms from late pregnancy
or early postpartum through 12 months postpartum. The LI arm experienced clinically
significant lower levels of insulin than the HW arm, statistically significant lower levels
of HDL cholesterol and TNF-a, and no differences in all other cardiovascular disease risk
and insulin resistance biomarkers. These findings suggest that an active lifestyle
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intervention among at-risk Hispanic women has a limited effect on cardiovascular disease
risk and insulin resistance biomarkers, potentially due to compliance or the duration, or
timing of the intervention. However, we also observed that above the median levels of
sports and exercise physical activity during the postpartum period was associated with
beneficial impacts on several cardiovascular disease risk and insulin resistance
biomarkers, suggesting that performing adequate intensity physical activity is necessary
to reduce cardiovascular disease and insulin resistance risk. Future studies should address
barriers to engagement in physical activity and healthy diets among this high-risk
population, including issues of participant stressors, low health literacy, and inequities in
social and physical environmental conditions experienced by Hispanic women, and focus
on the promotion of meeting physical activity guidelines (90,91).
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CHAPTER II
THE IMPACT OF A LIFESTYLE INTERVENTION ON PREGNANCY AND
POSTPARTUM CARDIOVASCULAR DISEASE RISK AND INSULIN
RESISTANCE BIOMARKERS AMONG OVERWEIGHT AND OBESE
HISPANIC WOMEN

A. Background and Significance
1. Public Health Impact of Prenatal and Postpartum Cardiovascular Disease Risk
Factors and Insulin Resistance Biomarkers
Systolic and diastolic blood pressure, lipid profiles (i.e., total cholesterol, low
density lipoprotein [LDL] cholesterol, high density lipoprotein [HDL] cholesterol, and
triglyceride concentration), and C-reactive protein (CRP) are markers of cardiovascular
health (1). An enhanced cardiovascular risk factor profile (e.g., elevated blood pressure,
total cholesterol, LDL cholesterol, triglyceride concentration, and CRP concentrations
and low HDL cholesterol) during pregnancy and the postpartum period are associated
with a higher risk of developed cardiovascular disease in the future (8). Cardiovascular
disease (e.g., stroke, atrial fibrillation, and atherosclerosis) could lead to sudden cardiac
death or heart failure later in life (2).
Among Hispanic women in the United States, between 2011 and 2014,
approximately 30.7% had high blood pressure and 41.2% had high total cholesterol (i.e.,
total cholesterol levels of 200 mg/dL or higher) (3). Hispanic women of Puerto Rican
descent have a significantly higher prevalence of hypertension and hypercholesterolemia
and are more likely to have at least three cardiovascular risk factors than Hispanic women
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of other descents (i.e., Cuban, Dominican, Mexican, Central and South American) (4).
Additionally, Hispanic women in the United States have a greater likelihood of having
elevated CRP protein levels (5) when compared to non-Hispanic women of European
descent (6).
Additionally, cardiovascular disease (e.g., coronary heart disease and stroke) is
the most common cause of mortality in Hispanic Americans (2). In U.S. Hispanic
women, heart disease is the second leading cause of death (7). Between 2011 and 2014,
33.3% of Hispanic women had cardiovascular disease, which was the cause of death in
approximately 23,350 Hispanic women in 2015 (3). However, Hispanic women of Puerto
Rican descent are more likely to have self-reported cardiovascular disease when
compared to Hispanic women of other descents (4). Additionally, Hispanic women have
high rates of overweight and obesity (78.8% & 48.9%, respectively), compared to nonHispanic whites (64.8% & 37.9%, respectively); women who are overweight or obese are
at increased risk of cardiovascular disease (92–94).
One of the cardiovascular changes during a normal pregnancy is a decrease in
peripheral resistance of the blood vessels. Therefore, during pregnancy systolic blood
pressure generally stays the same and there is a small decrease in diastolic blood
pressure. Blood pressure usually returns to pre-pregnancy levels during the postpartum
period (10,11). Although the causes are not well understood, in some women blood
pressure can increase during pregnancy (12). Gestational hypertension leads to the
development of preeclampsia (blood pressure  140/90 mmHg and presence of protein in
the urine), which is a disorder that can lead to multi-organ failure in pregnant women
(12). Overweight and obese women have a higher risk of preeclampsia compared to
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normal weight women (95). Additionally, women with hypertension or preeclampsia
during pregnancy are more likely to have high blood pressure during the postpartum
period and subsequent development of cardiovascular disease (13,95).
Total and LDL cholesterol also typically increased during pregnancy, with an
estimated 50% increase in total cholesterol, due to a need for production and function of
hormones and fetal development (14,15). Additionally, a two- to fourfold increase in
triglyceride concentrations occurs during pregnancy, with levels returning to prepregnancy concentrations during postpartum (15). Women with lipid profiles exceeding
the normal increases observed during pregnancy could also experience hyperlipidemia
into the postpartum period, and therefore increase the risk of atherosclerosis later in life.
Prior studies have observed that up to 50% of postpartum women had elevated
CRP levels 12 months after childbirth, with low socioeconomic status serving as a
significant predictor (16). Elevated CRP levels have been associated with the
development of inflammatory conditions, including cardiovascular disease and
atherosclerosis (24). However, all cardiovascular risk factor biomarkers typically return
to pre-pregnancy levels within 3 months postpartum (18–21).
Elevated levels of insulin, glucose, HbA1c, leptin, and HOMA and low levels of
adiponectin are markers of insulin resistance (22,23). Hispanic women in the United
States have higher prevalence of elevated insulin and glucose levels, when compared to
non-Hispanic white women (24,25). Specifically, 36.7% of Hispanic women in the
United States have elevated fasting plasma glucose levels, compared to 35.7% of nonHispanic white women (25). Additionally, Hispanic women in the United States have
higher HbA1c (19) (26), leptin (27), and lower adiponectin (29), when compared to non-
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Hispanic white women. It is also well recognized that overweight or obese BMI is
associated with an increased risk of type 2 diabetes (96).
Elevated insulin, glucose, HbA1c, leptin, and HOMA, and lower adiponectin
levels are associated with insulin resistance, an early step towards development of type 2
diabetes (22). Type 2 diabetes is the seventh leading cause of death in the United States
and is a risk factor for the development of cardiovascular disease, the leading cause of
death in the United States (30). The prevalence of type 2 diabetes among Hispanic
women in the United States is almost twice as high as among non-Hispanic white women
(11.6% vs. 6.6%), with 4.9 million Hispanic Americans having diagnosed diabetes and
rates only increasing (31). Additionally, it is estimated that an additional 1.5 million
Hispanic Americans have undiagnosed diabetes which can cause potentially severe
complications (31,32). Evidence of insulin resistance during pregnancy and postpartum
are associated with the development of gestational diabetes mellitus (GDM) during
pregnancy and type 2 diabetes in the future (33,35).
One of the normal changes that occurs during pregnancy is increased insulin
resistance in the mother to facilitate the transfer of glucose to the fetus (15). However,
some women develop abnormal insulin resistance or GDM during pregnancy which
results in exaggerated insulin resistance and impaired pancreatic function (15). It is wellknown that having GDM is associated with an increased risk of future type 2 diabetes,
with nearly 70% of women developing type 2 diabetes after 10 years postpartum (15,35).
Additionally, some insulin resistance biomarkers, such as HbA1c (36) and
adiponectin (18), lower during pregnancy, while others such as leptin (37–39) increase
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during pregnancy. However, all insulin resistance biomarkers typically return to prepregnancy levels within 3 months postpartum, and often much sooner than that (42–45).
Risk factors for cardiovascular disease and insulin resistance biomarkers during
the pregnancy and postpartum include non-modifiable factors (e.g., family history or
genetics), as well as modifiable risk factors such as smoking, physical inactivity, a diet of
poor quality or excess energy intake, and excess body weight (2,46). Additionally,
women with an overweight or obese BMI are more likely to have an adverse postpartum
cardiovascular risk and insulin resistance profile, as well as an increased risk of future
cardiovascular disease and type 2 diabetes (97). Hispanic overweight and obesity is likely
due to lower average socioeconomic status, differences in cultural factors, and barriers to
sustainable, culturally relevant weight management programs.

2. Mechanisms of Lifestyle Behaviors on Pregnancy and Postpartum Cardiovascular
Risk Factors and Insulin Resistance Biomarkers
Participation in regular physical activity or exercise and eating a quality diet have
been associated with improvements in cardiovascular disease risk and insulin resistance
profiles in the general adult population. However, the specific cellular mechanisms
between physical activity and diet on cardiovascular risk factors and insulin resistance are
not entirely clear.
Increasing physical activity has been found to lead to improvements in
cardiorespiratory fitness and insulin sensitivity (47). Improved fitness, in turn, has been
associated with: 1) decreases in oxidative stress, inflammation, and sympathetic nervous
system activity, and 2) increases in endothelial function, baroreflex sensitivity,
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lipoprotein lipase activity, hepatic glucose output, secretion of anti-inflammatory
cytokines, and parasympathetic nervous system activity (9,16,47).
Improving diet quality, primarily via a decrease in lipid consumption, has been
shown to improve blood lipid profiles (i.e., decreasing total cholesterol, LDL-C, and
triglycerides, and increasing HDL-C) by decreasing inflammation and altering lipid
pathways (9,16). However, despite acceptance that improved dietary quality, in many
forms, helps to reduce insulin resistance, the mechanisms by which such changes alter
insulin-signaling within relevant tissues is unclear (48,49).

3. Clinical Trials of Lifestyle Interventions on Pregnancy and Postpartum
Cardiovascular Risk Factors and Insulin Resistance Biomarkers
Fourteen trials have examined the effects of lifestyle interventions on
cardiovascular risk factors and insulin resistance biomarker outcomes in pregnant and
postpartum women (Table 1) (51,52,99–102,53–59,98). All of the studies used
randomized controlled trial designs (51,52,99–102,53–59,98). Of these studies, one was
conducted in the United States (57) and two were conducted among Hispanic women
(57,99). Additionally, only six of the studies were conducted among overweight and/or
obese women (51,57,98,100–102).
Only two of the interventions were initiated during pregnancy and completed in
the postpartum months (54,55), while six studies were conducted entirely during
pregnancy (53,98–102) and another six studies were conducted entirely during the
postpartum period (51,52,56–59). Both the studies that began during pregnancy and
continued into the postpartum period focused on diet only (54,55). Among the studies
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that occurred during pregnancy only, one focused on a physical activity intervention only
(53), while the other five studies focused on both physical activity and dietary
modifications (98–102). Lastly, among the studies that occurred during postpartum only,
three focused on both physical activity and dietary modifications (51,52,58) and three
focused on physical activity modifications only (56,57,59).
Of the twelve studies that included an exercise component, five involved
supervised exercise training interventions which included one to four sessions per week
of cycling, group and/or individual exercise classes, walking groups and promotion of
increased step counts per day (51,52,101,102,53,56–59,98–100). Of the nine studies that
included a dietary component, eight provided patient counseling via in person or
telephone sessions with a dietician (51,52,54,55,58,98,99,101). The one study that did not
provide patient counseling promoted a Mediterranean-style diet (100). Additionally, the
two studies who only had dietary interventions incorporated both counseling and either
probiotics (54) or breastfeeding support (55). Only three studies relied upon theoretical
models, including the Social Cognitive Theory and Control Theory (55,57,98).
Of the seven studies that evaluated blood pressure as an outcome, five found a
null association between their interventions and blood pressure (51–53,56,101), one
found a decrease in blood pressure (58) and one found an increase in systolic blood
pressure (57). All the studies evaluated cholesterol as an outcome, three found a decrease
in total cholesterol (51,54,58), five found a decrease in LDL cholesterol (Brekke,
Davenport, Hoppu, Ramirez-Velez, Zilberman-Kravits) (51,52,54,58,99), two found an
increase in HDL cholesterol (51,58) and nine were null) (53,55–57,59,98,100–102).
Among the studies that evaluated triglycerides as an outcome, two found a decrease in
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triglycerides (58,99), while the other twelve reported null findings (51,52,101,102,53–
57,59,98,100). In the nine studies that evaluated insulin as an outcome, four found a
decrease in insulin (53,56,58,101) while three were null (55,57,100) and one study found
a decrease in insulin during early postpartum but an increase over the first year
postpartum (51). In the eleven studies that evaluated glucose as an outcome, three found a
decrease in glucose (52,58,102) and eight were null (51,53,55–57,98,100,101). Both the
studies that evaluated HbA1c, were null (53,55). In the four studies that evaluated CRP
protein as an outcome, one study found a decrease in CRP in late pregnancy (100) while
the other three studies were null (51,53,55). All five studies that evaluated HOMA as an
outcome found a decrease in HOMA (53,56,58,101,102). The single study that evaluated
leptin found a null association (100) and the single study that evaluated adiponectin as an
outcome found an increase in adiponectin over postpartum.
Overall, the prior studies that incorporated both physical activity and dietary
interventions reported greater changes in cardiovascular risk factors and insulin resistance
biomarkers as compared to those studies whose interventions targeted physical activity or
diet alone.
In the only study to date that was performed among Hispanic women in the
United States, Vega-Lopez et al. performed a 2-arm randomized controlled trial among
44 postpartum Hispanic women (57). Women who were randomized into the intervention
arm participated in a postpartum walking intervention of moderate intensity with weekly
walking groups, support sessions and follow-up phone calls from study personnel for 12
months, while women in the control arm were provided weekly newsletters with
unrelated information and follow-up calls (57). This study was developed with the Social
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Support theoretical framework. When comparing the intervention arm to the control arm,
systolic blood pressure significantly increased by 8.0 mmHg (p=0.002) but there were no
observed, statistically significant differences between the arms with regards to diastolic
blood pressure, total cholesterol, HDL and LDL cholesterol, triglycerides, insulin or
glucose (57). However, this study was conducted in a small population of women (n=44),
which likely limited the power of the study to be able to detect any differences, if present.
Additionally, this study provided a physical activity only intervention which has been
shown to have a lesser effect on cardiovascular risk factors and insulin resistance
biomarkers than interventions that incorporate both physical activity and dietary
recommendations (51,52,58,60–62). Lastly, although Vega-Lopez et al. utilized the social
support theoretical framework, their study recruitment and methods were not culturally
tailored to Hispanic women (i.e., provided study materials in Spanish, tailored physical
activity recommendations to cultural values, attitudes, beliefs and norms) (57).
In summary, the prior epidemiologic studies of lifestyle interventions and
cardiovascular risk and insulin resistance biomarkers have several limitations: 1) the vast
majority were performed outside of the U.S. or in non-Hispanic populations who are at
lower risk of type 2 diabetes, 2) only two out of the fourteen studies were initiated during
pregnancy and followed through the postpartum period, and 3) the majority had physical
activity and/or dietary interventions that required participants to go to a location, making
them less accessible and more cost-prohibitive than at-home interventions. Therefore, we
propose to evaluate the effect of a physical activity and dietary intervention on
cardiovascular risk and insulin resistance biomarkers among approximately 100 Hispanic
women, identified as overweight or obese, in Massachusetts during early pregnancy
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through one year postpartum. The lifestyle intervention was culturally modified,
motivationally targeted and individually tailored to Hispanic women in the U.S. and was
provided to women primarily through mail-based intervention materials and telephone
counseling sessions, reducing the burden of participants and the cost of delivery.

4. Summary of Significance and Innovation
The American Heart Association posits that to successfully reduce cardiovascular
disease risk, approaches should be individually-tailored and provide prevention and
treatment at the individual level (5). Therefore, we propose to evaluate the effect of a
culturally modified, motivationally targeted and individually tailored lifestyle
intervention on cardiovascular risk and insulin resistance biomarkers among overweight
and obese Hispanic women. This study is significant in that it targets an ethnic group that
has high rates of modifiable risk factors for cardiovascular disease (e.g., physical
inactivity and overweight or obese BMI) by intervening at the beginning of the prenatal
period and continuing through postpartum. Additionally, this approach is innovative due
to its utilization of a theory-based, individualized lifestyle intervention in a minority
population that includes novel materials to target cardiovascular risk factors and insulin
resistance biomarkers and would be readily translatable into clinical practice in this highrisk population at a low cost.
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B. Specific Aims and Hypotheses
Specific Aim #1: Evaluate the impact of a lifestyle intervention on pregnancy and
postpartum biomarkers of cardiovascular risk among overweight and obese Hispanic
women.
Hypothesis #1: Participants randomized to the Lifestyle Intervention (LI) arm
will have lower total cholesterol, LDL cholesterol, triglyceride concentrations,
systolic and diastolic blood pressure, CRP, and higher HDL cholesterol,
compared to participants randomized to the comparison Health and Wellness
(HW) arm.

Specific Aim #2: Evaluate the impact of a lifestyle intervention on pregnancy and
postpartum biomarkers of insulin resistance among overweight and obese Hispanic
women.
Hypothesis #2: Participants randomized to the Lifestyle Intervention will have
lower fasting concentrations of glucose, insulin, HbA1c, leptin, lower HOMA and
higher concentrations of adiponectin, compared to participants randomized to the
comparison HW arm.

C. Study Design and Methods
1. Study Design
Proyecto Mamá was a randomized controlled trial designed to test the efficacy of
a culturally and linguistically modified, individually tailored lifestyle intervention to
improve maternal metabolic status, including postpartum cardiovascular risk and insulin
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resistance biomarkers, among overweight/obese Hispanic women. Eligible women were
recruited in early pregnancy (~10 weeks gestation) and randomly assigned to either a
Lifestyle Intervention (treatment arm) or a Comparison Health and Wellness Intervention
(control arm) (Figure 2). Randomization occurred at ~12 weeks gestation, after
completion of the baseline assessment, and was stratified based on age and pre-pregnancy
BMI. The intervention began with an Active Intervention Period (i.e., ~12 weeks
gestation through 6 months postpartum), followed by a Follow-Up Period (i.e., 6 months
postpartum through 12 months postpartum). At enrollment during early pregnancy (i.e.,
10 weeks gestation), a fasting blood sample was collected, and blood pressure was
measured. A subsequent fasting blood sample was collected at mid-pregnancy (i.e., 24-28
weeks gestation) and late pregnancy (i.e., 32-34 weeks gestation) as well as during the
postpartum period at 6 weeks, 6 months and 12 months postpartum. All protocols were
approved by the Institutional Review Boards at the University of Massachusetts Amherst
and Baystate Health. Details of the study have been previously published (103).

2. Study Population
Proyecto Mamá was conducted at the ambulatory obstetrical practices of Baystate
Medical Center located in Western Massachusetts. Inclusion criteria included pregnant
Hispanic women in early pregnancy (~10 weeks gestation) who were overweight or
obese (BMI >= 25 kg/m2) and 18-45 years of age. Exclusion criteria included: 1) prepregnancy BMI <25 kg/m2, 2) history of type 2 diabetes, heart disease, or chronic renal
disease, 3) contraindications to participation in moderate physical activity or to a lowfat/high-fiber diet (e.g., Crohn’s disease, ulcerative colitis), 4) inability to read English or
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Spanish at a 6th grade level, 4) <16 or >45 years of age, 5) >16 weeks gestation, 6)
current medications which adversely influenced glucose tolerance, 7) not planning to
continue to term or deliver at the study site, or 8) multiple pregnancy (e.g., twins, triplets,
etc.).

3. Intervention
The Lifestyle Intervention was an evidence-based approach utilizing culturally
and linguistically modified, motivationally targeted, individually-tailed intervention
materials developed in previous randomized controlled trials in Hispanic populations
(63–66,104–107) as well as theoretical concepts and strategies from the Social Cognitive
Theory (108) and the Transtheoretical Model (68).
First, the Prenatal Phase (~12 weeks gestation to delivery) began with a face-toface introductory session, which built upon the usual prenatal care received by patients.
The goal of this session was to optimize gestational weight gain via setting a gestational
weight gain goal, providing individually tailored encouragement and resources for how to
meet that goal via better regulation of personal diet and exercise behaviors. Motivational
interviewing was used to identify and strengthen participants’ motivations for change.
Over the remainder of pregnancy, biweekly and monthly mailed print-based materials
and telephone booster calls were used to provide motivationally based individualized
feedback. Tailoring questionnaires, including surveys on diet and exercise, were mailed
to participants to assess their self-efficacy for changing lifestyle factors and the stages
and factors associated with change and personal preferences towards types of exercise
and foods (103). Based on responses to the monthly mailed tailoring questionnaires,
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individualized reports were sent to participants, in preferred languages at an accessible
reading level. Lastly, the Prenatal Phase ended with a third trimester face-to-face session
(~34 weeks gestation) to target participants’ knowledge and attitudes regarding
postpartum weight loss and type 2 diabetes prevention, preparing for the Active
Postpartum Phase.
Second, the Active Postpartum Phase (6 weeks postpartum to 6 months
postpartum) began with a face-to-face session. At this session, the tailoring
questionnaires were repeated and physical activity, dietary and weight loss goals based
on pre-pregnancy BMI were set. Participants were encouraged to work towards their
goals via reinforcement of their own weight loss motivations. This face-to-face session
was followed by monthly mailed, print-based materials and telephone booster calls to
provide motivationally based individualized feedback incorporating progress review,
problem-solving discussion, and goal setting assistance.
Lastly, the Maintenance Postpartum Phase (6 months to 12 months postpartum)
continued with mailed, print-based materials and telephone booster calls, as in the Active
Postpartum Phase, but at a lesser frequency.

4. Comparison
The Health and Wellness comparison arm received mailed health materials and
telephone booster calls at the same frequency as the Lifestyle Intervention participants, to
control for contact time. However, materials focused on non-exercise and non-dietary
topics, so the content remained distinct from that provided to the Lifestyle Intervention
arm.
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5. Outcome Variables: Pregnancy and Postpartum Cardiovascular Risk and Insulin
Resistance Measures
Biomarkers of cardiovascular risk included systolic and diastolic blood pressure,
blood lipids (i.e., total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides)
and CRP (Table 0). Biomarkers of insulin resistance included insulin, glucose, HbA1c,
leptin, adiponectin and HOMA (Table 0).
Blood pressure was measured during all pregnancy and postpartum visits with an
automated Omron Blood Pressure Monitor with the cuff placed on the upper arm over the
brachial artery. The Omron Blood Pressure Monitors have been validated to assess blood
pressure within an error range of 3 mmHg (or 2%), which is within the Association of
Medical Instrumentation standards. Systolic and diastolic blood pressure readings were
reported as continuous variables.
Blood lipids were measured using the Roche P Modular system during midpregnancy and postpartum. Total cholesterol was measured using enzymatic methods
(109). Day-to-day reproducibility have been reported as 1.7% (SD = 2.4 mg/dL) and
1.6% for cholesterol concentrations of 132.8 and 280.4 mg/dL, respectively (109). A
homogenous direct method was used to determine LDL cholesterol (37). Day-to-day
variabilities of LDL cholesterol with this method have been reported as 3.01, 2.34, and
2.18% for concentrations of 90, 106, and 129 mg/dL, respectively. A direct enzymatic
colorimetric assay was used to determine HDL cholesterol (36). The day-to-day
reproducibility for HDL cholesterol concentrations of 27.0 and 54.9 mg/dL were reported
as 3.3% (SD = 0.9) and 1.7% (SD = 0.9), respectively. Triglycerides were also measured
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enzymatically, but with a correction for endogenous glycerol (38). Day-to-day
reproducibility of 1.8% (SD = 1.6) and 1.7% (SD = 3.5) were reported for concentrations
of 84.0 and 201.8 gm/dL, respectively. All blood lipid data were analyzed as continuous
variables.
High sensitivity CRP protein was measured during mid-pregnancy and
postpartum on the Roche P Modular system with an immunoturbidimetric assay with
reagents and calibrators from DiaSorin (Stillwater, MN). CRP concentrations of 0.91,
3.07, and 13.38 mg/L have reported day-to-day variabilities of the assay of 2.81, 1.61,
and 1.1%, respectively. CRP was analyzed as a continuous variable.
Insulin, glucose and HbA1c were measured during pregnancy and postpartum.
Fasting insulin (FI) was measured by an electrochemiluminescence immunoassay on the
Roche E Modular system. The lowest detection limit of this assay is 0.2 uU/mL and the
day-to-day imprecision values at concentrations of 6.36, 20.9 and 747 uU/mL have been
reported as 2.6%, 2.8% and 2.5%, respectively. Fasting glucose (FG) was measured
enzymatically on the Roche P Modular system using Roche Diagnostics reagents (75).
Day-to-day variability of glucose concentrations of 90 and 312 mg/dL have been reported
as 1.7% and 1.6%, respectively. HbA1c determination on the Roche R Modular system
was based on turbidimetric immunoinhibition using packed red cells. The day-to-day
variability at values of 5.5 and 9.1 have been reported as 1.9% and 3.0%, respectively.
Leptin was measured during pregnancy and postpartum using an ultra-sensitive
ELISA assay, an enzymatically amplified “two-step” sandwich-type immunoassay (R&D
Systems, Minneapolis, MN). The day-to-day variability at concentrations of 65.7, 146
and 581 pg/mL has been reported as 5.4%, 4.2% and 3.5%, respectively.
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Adiponectin was measured during pregnancy and postpartum using an ELISA
method from ALPCO Diagnostics Inc. (Salem, NH). The day-to-day variability at 9130
and 3930 have been reported as 9.8% and 10.2%, respectively.
Homeostasis Model Assessment (HOMA) will be calculated as [(FI x FG)/22.5]
on a scale of 1 to 8.

6. Covariate Measures
Medical history variables included pre-pregnancy body mass index (BMI), family
history of diabetes, and parity and were extracted from medical records at study
enrollment (Table 1). All medical history variables will be presented categorically.
Clinical characteristics of the current pregnancy included gestational weight gain,
glucose tolerance, and confirmed diagnoses of hypertension or preeclampsia. Glucose
tolerance, gestational weight gain, and confirmed diagnoses of hypertension or
preeclampsia were obtained from medical records at all times points during pregnancy
(103). Maternal weight in kilograms was assessed at each medical visit during pregnancy.
Gestational weight gain was determined as the difference between maternal weight at
delivery and pre-pregnancy weight and will be categorized as below, within, or above the
2009 Institute of Medicine gestational weight gain guidelines (76). Glucose tolerance test
results were also extracted from medical records for all time points during pregnancy and
will be categorized as normal, isolated hyperglycemia, impaired glucose tolerance, or
gestational diabetes mellitus (3).
Pre-pregnancy smoking, smoking during pregnancy, and alcohol use during
pregnancy were self-reported at study enrollment and throughout pregnancy using the

104

Pregnancy Risk Assessment Monitoring System and will be categorized as yes or no
responses (78). Depression was measured using the Edinburgh Postpartum Depression
Scale during the postpartum period (110). At least probable minor depression will be
defined as having a score of at least 13 on that scale and will be dichotomized as yes or
no. Sleep was measured using the Pittsburgh Sleep Quality Index (PSQI) during the
postpartum period (111). The total sleep score will be derived from the PSQI and will be
presented continuously with a lower score representing better sleep.
Sociodemographic measures were collected from self-report at study enrollment
and included age, education, annual household income, marital status, generation in the
U.S., living with spouse or partner, number of adults living in the same household (18
years or older), and number of children living in the household (under 18 years).
Psychological acculturation status was also measured at enrollment using the
Psychological Acculturation Scale (80) and will be categorized as low acculturation
(scoring 1 to less than 3 on the scale) or high acculturation (greater than 3 on the scale).

D. Data Analysis

Specific Aim #1: Evaluate the impact of a lifestyle intervention on pregnancy and
postpartum biomarkers of cardiovascular risk among overweight and obese Hispanic
women.
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Specific Aim #2: Evaluate the impact of a lifestyle intervention on pregnancy and
postpartum biomarkers of insulin resistance among overweight and obese Hispanic
women.

1. Univariate Analyses
The number and percentage of participants who were recruited and were excluded
are presented (Figure 2). We also assessed the means and standard deviations of the
cardiovascular risk and insulin resistance biomarker outcome variables at the early
pregnancy (~10 weeks gestation) baseline.

2. Bivariate Analyses
We used two-sample t-tests and chi square tests to determine if the intervention
arms had different distributions of covariates at baseline (i.e., early to mid-pregnancy)
(Table 2.1).

3. Multivariable Analyses
An intent to treat analysis was used to evaluate differences in the changes of
cardiovascular disease risk factors and insulin resistance biomarkers between the
intervention arms from baseline (early to mid-pregnancy) to late pregnancy, 6 weeks, 6
months, and 12 months postpartum. Within group differences in mean changes from
baseline to each following time point were assessed using two-sample t-tests among both
treatment arms (Table 2.2). Between arm differences in change and percent change in
each cardiovascular risk and insulin resistance biomarker outcome variable were assessed
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using two-sample t-tests and a mixed effect model with random subject effects, including
a common mean at baseline for the treatment arms (groups), a time effect, and a group by
time interaction (Tables 2.3 & 2.4) (81). Specifically, mixed models were used to
evaluate differences in the change in cardiovascular risk and insulin resistance
biomarkers from baseline to 12 months postpartum between the intervention groups.
These models accounted for the repeated measures of cardiovascular risk and insulin
resistance biomarkers with random subject effects and incorporated fixed assessment
time effects using baseline cardiovascular risk and insulin resistance biomarkers as the
reference.

4. Sensitivity Analyses
We will perform several sensitivity analyses. First, we conducted two-sample ttests and chi-square tests to evaluate whether the final analysis group had different
distributions of covariates at baseline as compared to those who were excluded from the
analysis due to missing data (Table 2.5). Second, we limited the analysis to women in the
LI who were compliant with the intervention defined as: 1) meeting the ACOG exercise
guidelines and 2) returning >1 tailoring questionnaires during the postpartum period to
evaluate whether receiving the planned dose of the intervention affects differences in
cardiovascular risk and insulin resistance biomarkers between the intervention arms
(Table 2.6). Third, we limited the analysis to women who had abnormal glucose tolerance
during pregnancy – an additional risk factor for CVD and type 2 diabetes – to evaluate
whether inclusion of this additional risk factor would affect differences in cardiovascular
risk and insulin resistance biomarkers between the intervention arms (Table 2.7). Fourth,
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we assessed whether type and intensity of self-reported physical activity, regardless of
the assigned intervention arm is associated with change in cardiovascular risk and insulin
resistance biomarkers (Table 2.8). Lastly, we assessed whether participants who were
adherent to ACOG guidelines of physical activity, regardless of the assigned intervention
arm, had different distributions of covariates at baseline as compared to those who were
non-adherent to ACOG guidelines of physical activity (Table 2.9).

E. Results
The final analytic sample included 54 participants in the Lifestyle Intervention
(LI) arm and 61 participants in the Health and Wellness (HW) arm. Participants in the LI
and HW arms were largely comparable according to covariates, however participants in
the LI arm had significantly higher systolic blood pressure than participants in the HW
arm (118.39 mmHg vs. 112.09 mmHg, p=0.02) (Table 2.1).
We then evaluated the within-arm change in biomarkers from baseline through
mid-pregnancy, late pregnancy, 6 weeks, 6 months, and 12 months postpartum (Table
2.2). In both the LI and HW arms, total cholesterol, HDL cholesterol, triglycerides, and
adiponectin significantly decreased from early pregnancy through 12 months postpartum
(Table 2.2). Additionally, across both arms, LDL cholesterol, insulin, leptin, and HOMA
significantly increased from early pregnancy through late pregnancy with the HW arm
having persistent increases in insulin and HOMA into early postpartum (Table 2.2).
HbA1c also significantly increased from early pregnancy through the postpartum period
across both the LI and HW arms (Table 2.2). However, among the LI arm only, glucose
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increased at from early pregnancy to 6 months postpartum, while among the HW arm
only, CRP decreased from early pregnancy to each postpartum time point (Table 2.2).
Next, we evaluated the differences in mean change (Table 2.3) and the differences
in mean percent change (Table 2.4) from early pregnancy to each follow-up time point
between the intervention arms. We observed no differences in mean change nor percent
change among the cardiovascular risk and insulin resistance biomarkers (Table 2.3 &
Table 2.4).
We then conducted several sensitivity analyses. First, we evaluated whether there
were differences in the distribution of covariates and baseline biomarkers between those
women who were lost to follow-up compared to those who were not (Table 2.5). Women
who were lost to follow-up did not differ from those not lost according to the majority of
covariates but did have higher rates of living without a spouse or partner, having more
children, and higher baseline concentrations of LDL cholesterol (analysis: 107.31 mg/dL
vs. bias: 123.62 mg/dL) (Table 2.5).
Secondly, we evaluated whether findings differed according to adherence with the
intervention as defined as compliance with the ACOG guidelines (LI: 72%) or the return
of the PATQ tailoring questionnaires (LI: 79% and HW: 90%) (Table 2.6). In this per
protocol analysis, the majority of cardiovascular risk and insulin resistance biomarkers
showed no differences in change among those who were adherent to the intervention
(Table 2.6). However, among those who were adherent to the ACOG guidelines and
separately returned the tailoring questionnaire, there was a statistically significant
difference in change in HDL cholesterol from early pregnancy through 12 months
postpartum in the LI arm compared to the HW arm, with the LI arm experiencing higher
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HDL cholesterol concentrations (p=0.04) (Table 2.6). Additionally, there was a
statistically significant difference in change in LDL cholesterol from early pregnancy to
12 months postpartum, among those who were adherent to the ACOG guidelines, with
the LI arm having a greater increase in LDL cholesterol compared to the HW arm
(beta=12.30, 95% CI: 3.56, 21.05) (Table 2.6). When comparing the characteristics of
those who were adherent to the ACOG guidelines, compared to those who were
nonadherent, we observed no differences in the distribution of covariates across the
groups (results not shown).
Third, we evaluated whether the effect of the intervention differed among women
who had an abnormal glucose tolerance during pregnancy (Table 2.7). Approximately
29% of women in the LI arm and 30% of women in the HW arm had abnormal glucose
tolerance during pregnancy (Table 2.7). We observed no differences in change between
the LI and HW arms for the majority of cardiovascular risk and insulin resistance
biomarkers among those who had abnormal glucose tolerance during pregnancy (Table
2.7). However, we observed a statistically significant difference in change in HDL
cholesterol from early pregnancy through 12 months postpartum in the LI arm compared
to the HW arm, with the LI arm experiencing greater increase in HDL cholesterol
concentrations (p=0.03) (Table 2.7).
Lastly, we evaluated whether different intensities and types of physical activity,
as opposed to assigned intervention arm, affected the cardiovascular risk and insulin
resistance biomarkers from early pregnancy through 12 months postpartum (Tables 2.8a2.8k). We found statistically significant differences in change in all cardiovascular risk
and insulin resistance biomarkers across intensities and types of physical activity (Tables
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2.8a-2.8k). Specifically, participation in above the median levels of moderate, vigorous,
combined moderate-vigorous, occupational, and sports/exercise activity and meeting the
ACOG guidelines was associated with significant differences in change in cardiovascular
risk biomarkers with those participating in activity above the median having better
cardiovascular risk profiles than those with activity below the median (Tables 2.8a-2.8e).
Participation in above the median moderate, vigorous, combined moderate-vigorous,
household/caregiving, and occupational activity was associated with significant
differences in change in insulin resistance biomarkers with those participating in activity
above the median having better insulin resistance profiles than those with activity below
the median (Tables 2.8f-2.8k).

F. Discussion
In this randomized controlled trial among overweight and obese Hispanic
pregnant women, we found that a culturally modified, individually tailored lifestyle
intervention did not lead to a significant difference in change over postpartum follow-up
time in the majority of cardiovascular disease risk and insulin resistance biomarkers as
compared to the HW control arm. However, contrary to expectations, the LI arm had
higher LDL cholesterol concentrations than the HW arm over the course of pregnancy
through 12 months postpartum. Additionally, we observed that women who participated
in vigorous physical activity during pregnancy and postpartum – regardless of their
assigned intervention arm – had significantly improved levels of several cardiovascular
disease and insulin resistance biomarkers, including cholesterol, insulin, and glucose.
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Our findings of the lack of a positive influence of the lifestyle intervention on all
cardiovascular disease and insulin resistance biomarkers, except LDL cholesterol,
between the intervention arms are consistent with some (55,57,59,98) but not all studies
(51–54,56,58,99–102). Similar to our study, Martin et al., Mills et al., and Vega-Lopez et
al. developed their intervention using theoretical models such as Social Cognitive Theory
or social support and were all conducted among small samples (36, 44, and 37 women,
respectively) (55,57,98). The study by Vega-Lopez et al. was the only prior intervention
that was also conducted among an entirely US-based Hispanic population (57).
Specifically, this study was conducted among 44 postpartum Hispanic women, largely
born outside of the US, and involved a 12-month postpartum walking intervention of
moderate intensity with weekly walking groups, support sessions and follow-up phone
calls (57). The intervention was based on a theoretical framework (e.g., Social Support)
and utilized a contact-time comparison arm, similar to our study (57). Unlike our study,
however, their intervention materials were not culturally tailored to Hispanic women
(57). The authors found no statistically significant differences between the arms with
regards to diastolic blood pressure, total cholesterol, HDL and LDL cholesterol,
triglycerides, insulin nor glucose (57).
In contrast, five of the prior studies found that a lifestyle intervention led to a
statistically significant decrease in LDL cholesterol ranging from 3.8 to 36.2 mg/dL
(51,52,54,58,99), a decrease in insulin ranging from 0.5 to 5.9 uIU/mL (51,53,56,58,101),
and a decrease in HOMA ranging from 0.3 to 1.5 (53,56,58,101,102). Differences
between the current study and these prior studies are likely due to differences in study
methods. For example, only one of the prior fourteen studies were conducted in the
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United States (57), with populations from several other geographic areas including
northern Europe, Canada, Australia, Columbia, China, Israel, and Greece, and many
studies were not restricted to those who were overweight or obese at pre-pregnancy.
Women who enter pregnancy with an overweight or obese BMI are already at a higher
risk for the development of cardiovascular disease and type 2 diabetes, compared to
normal weight women. However, this group may find it more difficult to meet physical
activity and dietary guidelines (112,113), due to stricter guidance and differing
perceptions around activity, that may result in beneficial impacts on their cardiovascular
disease and type 2 diabetes risk. Additionally, each study intervention had varying
timing, duration, and type of intervention. For example, these studies largely conducted
the intervention using supervised (52,53,56,58,99,101,102) or group physical activity
and/or dietary sessions (54,58,101). In contrast, the current study encouraged
individualized behavior change at home (e.g., unsupervised). Two studies with the
longest active intervention periods (i.e., 19-20 months during gestation and postpartum or
postpartum alone) saw consistently beneficial impacts of the intervention on
cardiovascular and/or insulin resistance biomarkers (54,58). In contrast, the current study
had a 12-month active intervention, from early pregnancy to 6 months postpartum.
Our observation of an adverse impact of the lifestyle intervention on LDL
cholesterol, is inconsistent with prior literature that either observed a significant decrease
in LDL cholesterol among the intervention arm (51,52,54,58,99) or no difference in LDL
cholesterol between the intervention arms (53,55–57,59,98,100–102). It is unlikely that
the lifestyle intervention led to an adverse impact on LDL as one would have expected a
similar corresponding negative impact on total cholesterol and HDL cholesterol as well.
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LDL is largely impacted by obesity, lack of exercise and good diet, smoking, and alcohol
consumption (84). Therefore, it is most likely that this observation is due to chance given
the multiple comparisons performed, the small sample size of our study particularly at 12
months postpartum (n=40), and the borderline significance of this finding.
Our findings of a beneficial impact of some vigorous physical activity during
pregnancy and postpartum on several cardiovascular disease risk and insulin resistance
biomarkers, regardless of the assigned intervention, is consistent with prior literature
(85,86). This suggests that in our study population, if the lifestyle intervention could lead
to the performance of vigorous physical activity, then it would likely have a positive
impact on cardiovascular disease and insulin resistance risk in this study population
during the postpartum period. However, we note that compliance with our lifestyle
intervention ranged from 72% among the lifestyle intervention arm to 52% among the
HW arm, over the postpartum period. In addition, our intervention was focused on
encouraging women to meet ACOG guidelines of 30 minutes of activity on most days of
the week. These ACOG guidelines may be too modest to impact cardiovascular disease
risk and insulin resistance biomarkers among this high-risk group.
Lastly, it is possible that a beneficial impact on cardiovascular disease risk and
insulin resistance biomarkers is limited to women who participated in physical activity
prior to pregnancy and through early pregnancy. This is supported by a meta-analysis that
demonstrated an association between greater total physical activity during pre-pregnancy
and early pregnancy and lower risk of gestational diabetes mellitus (114). It is possible
that women who are more physically active prior to pregnancy would have higher
compliance to the lifestyle intervention, if assigned. In the current study, although we did
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not measure pre-pregnancy activity, we measured early pregnancy physical activity
where women reported conducting an average of 1 MET-hour per week of vigorous
physical activity, with no observed differences between the intervention arms nor with
likelihood of meeting ACOG guidelines during the postpartum period. Additionally,
differing findings between the current study and prior studies could be due to differences
in the pre-pregnancy activity levels of participants as studies with participants who
partook in greater pre-pregnancy physical activity may have more advantageous
cardiovascular disease risk and insulin resistance biomarkers because of their long-term
physical activity participation and self-efficacy. This reinforces promotion of established
physical activity guidelines for women prior to pregnancy as well as during pregnancy
and postpartum.
This study has several limitations. First, non-differential misclassification of the
assigned intervention arm could have occurred in this study in the per protocol analysis.
Participants who had been randomized to the LI arm could have performed little physical
activity and dietary modifications, while participants who had been randomized to the
HW arm could have performed recommended levels of physical activity and dietary
modifications. This is likely to have occurred, given that not all participants randomized
to the intervention will follow the provided recommendations and intervention, while
participants randomized to the control group may change their habits regardless of the
study or due to the social supports provided. Specifically, we observed that 27% of the LI
arm did not meet the ACOG guidelines at any time postpartum, while 53% of the HW
arm did. However, we observed no differences in the distribution of covariates among
those who were ACOG compliant compared to those who were not. Additionally, this
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study’s utilization of a control arm matched for contact time minimizes the concern that
social support alone led to any observed changes, as opposed to changes being due to the
lifestyle content of the intervention. Finally, to the extent that non-differential
misclassification of the assigned intervention arm occurred, it would bias the results from
the intent-to-treat results towards the null. However, our allocation system, utilized by the
health educators and assessors, makes this concern highly unlikely (103).
Additionally, non-differential misclassification of the cardiovascular risk and
insulin resistance biomarkers could have occurred due to laboratory error, if the
biomarkers of interest had unexpected variability, or if they did not reflect what was
intended to measure. For example, if blood pressure measures had large within-person
variability or if they reflected only short vs. long-term levels then there could be nondifferential misclassification of blood pressure. If non-differential misclassification of the
cardiovascular risk and insulin resistance biomarkers had occurred it would bias the
results towards the null; however, this is concern is reduced given the low coefficients of
variation for the biomarkers of interest, the use of best practices in biomarker measures,
and the likelihood of the effect being non-differential between the intervention arms.
Despite the substantial loss to follow-up in this study (25%), differential loss to
follow-up is unlikely to have occurred since we observed similar loss to follow-up for
both randomization arms (LI: 67%, HW: 75%). This, in combination with the comparable
distribution of covariates among those who were included in the analysis group and those
who were missing all biomarker measures, minimizes the concern about differential loss
to follow-up.
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Information bias, where information on the biomarkers of interest were obtained
differently between the two intervention arms or where one arm was followed more
closely than the other, is unlikely to have occurred in this study. The methods for
obtaining and analyzing the cardiovascular risk and insulin resistance biomarkers were
the same for both treatment arms and assessors of the biomarkers of interest were blinded
to the treatment arm of participants.
Confounding is unlikely to have affected this study due to the use of
randomization. When comparing the distribution of covariates between the intervention
arms, we observed no differences in covariate distributions. However, it is possible that
randomization did not result in the comparable distribution of unknown covariates and
therefore, residual confounding could remain.
Lastly, due to the cultural tailoring of the provided intervention and the restriction
to overweight and obese women, the results of this study should be limited to other
Hispanic postpartum women who had an overweight or obese pre-pregnancy BMI.
There is physiologic evidence that participation in physical activity and
consuming a quality diet may contribute to advantageous changes in CVD and insulin
resistance biomarkers via decreases in oxidative stress, inflammation, sympathetic
nervous system activity, altered lipid pathways, and secretion of anti-inflammatory
cytokines ((9,16,47). However, when evaluating CVD biomarkers, we observed an
adverse greater increase in LDL cholesterol among the LI arm, compared to the HW arm,
from early pregnancy through 12 months postpartum. This adverse increase in LDL
cholesterol was not accompanied by associated adverse changes in total cholesterol nor
HDL cholesterol. Additionally, the intervention arms had different baseline LDL
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cholesterol concentrations with the x arm having more disadvantageous LDL than the x
arm (LI: 112.36 mg/dL; HW: 102.87 mg/dL). Although these differences were not
statistically significant (p=0.12), they could have influenced the differences in the
observed trends in change in LDL over time. These factors minimize concern that this
association reflects a true biological change in LDL cholesterol and instead suggest that
this observed association is largely due to chance.
In summary, in this randomized controlled trial of a culturally tailored,
individually modified lifestyle intervention among overweight and obese Hispanic
women we observed a significant difference in LDL cholesterol concentrations between
the intervention arms across early pregnancy through 12 months postpartum, with the LI
arm experiencing higher levels of LDL cholesterol than the HW arm, but no differences
in all other cardiovascular disease risk and insulin resistance biomarkers. These findings
suggest that an active lifestyle intervention among at-risk Hispanic women has a limited
to no effect on cardiovascular disease risk and insulin resistance biomarkers, potentially
due to compliance or the duration and intensity of the intervention. However, we
observed that some vigorous physical activity during pregnancy and postpartum was
associated with beneficial impacts on several cardiovascular disease risk and insulin
resistance biomarkers, suggesting that performing adequate intensity physical activity is
necessary to reduce cardiovascular disease and insulin resistance risk. Future studies
should address barriers to engagement in physical activity and healthy diets among this
high-risk population, including issues of participant stressors, low health literacy, and
inequities in social and physical environmental conditions experienced by Hispanic
women, and focus on the promotion of meeting physical activity guidelines (90,91).
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Table 2.1. Distribution of Covariates across the Lifestyle and Health & Wellness
Intervention Arms; Proyecto Mamá 2014-2017.
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Table 2.1., continued
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Table 2.2. Within-arm Univariate and Change in Cardiovascular Disease Risk and Insulin Resistance Biomarkers at Early Pregnancy
Baseline through 12 Months Postpartum; Proyecto Mamá 2014-2017.
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Table 2.2., continued
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Table 2.3. Between-arm Differences in Change in Cardiovascular Disease Risk and Insulin Resistance Biomarkers from Early
Pregnancy Baseline through 12 Months Postpartum; Proyecto Mamá 2014-2017.
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Table 2.3., continued
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Table 2.4. Between-arm Differences in Percent Change in Cardiovascular Disease Risk and Insulin Resistance Biomarkers from Early
Pregnancy Baseline through 12 Months Postpartum; Proyecto Mamá 2014-2017.
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Table 2.4., continued
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Table 2.5. Distribution of Covariates across Participants Included in Analysis and
Participants Missing All Biomarker Data; Proyecto Mamá 2014-2017.
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Table 2.5., continued
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Table 2.6. Between-arm Differences in Change in Cardiovascular Disease Risk and Insulin Resistance Biomarkers from Early
Pregnancy Baseline through 12 Months Postpartum among Adherent Participants; Proyecto Mamá 2014-2017.
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Table 2.7. Between-arm Differences in Change in Cardiovascular Disease Risk and Insulin Resistance Biomarkers from Early
Pregnancy Baseline through 12 Months Postpartum among Participants with Abnormal Glucose Tolerance During Pregnancy;
Proyecto Mamá 2014-2017.
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Table 2.8a. Impact of Actual Physical Activity on Between-Arm Differences in Change in Total Cholesterol; Proyecto Mamá 20142017.
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Table 2.8a., continued
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Table 2.8b. Impact of Actual Physical Activity on Between-Arm Differences in Change in LDL Cholesterol; Proyecto Mamá 20142017.
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Table 2.8b., continued
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Table 2.8c. Impact of Actual Physical Activity on Between-Arm Differences in Change in HDL Cholesterol; Proyecto Mamá 20142017.
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Table 2.8c., continued
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Table 2.8d. Impact of Actual Physical Activity on Between-arm Differences in Change in Triglycerides; Proyecto Mamá 2014-2017.
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Table 2.8d., continued
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Table 2.8e. Impact of Actual Physical Activity on Between-Arm Differences in Change in C-Reactive Protein; Proyecto Mamá 20142017.
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Table 2.8e., continued
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Table 2.8f. Impact of Actual Physical Activity on Between-Arm Differences in Change in Insulin; Proyecto Mamá 2014-2017.
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Table 2.8f., continued
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Table 2.8g. Impact of Actual Physical Activity on Between-Arm Differences in Change in Glucose; Proyecto Mamá 2014-2017.
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Table 2.8g., continued
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Table 2.8h. Impact of Actual Physical Activity on Between-Arm Differences in Change in HbA1c; Proyecto Mamá 2014-2017.
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Table 2.8h., continued
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Table 2.8i. Impact of Actual Physical Activity on Between-Arm Differences in Change in Adiponectin; Proyecto Mamá 2014-2017.
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Table 2.8i., continued

148

Table 2.8j. Impact of Actual Physical Activity on Between-Arm Differences in Change in Leptin; Proyecto Mamá 2014-2017.
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Table 2.8j., continued
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Table 2.8k. Impact of Actual Physical Activity on Between-arm Differences in Change in HOMA; Proyecto Mamá 2014-2017.
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Table 2.8k., continued
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Figure 2. Participant Flow Figure; Proyecto Mamá 2014-2017.
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CHAPTER III
THE IMPACT OF A LIFESTYLE INTERVENTION ON POSTPARTUM
WEIGHT RETENTION AMONG OVERWEIGHT AND OBESE HISPANIC
WOMEN

A. Background and Significance
1. Public Health Impact of Postpartum Weight Retention
Postpartum weight retention (PPWR) is the difference in weight from a selected
post-delivery time point and weight prior to pregnancy (115). An estimated 75% of
women have postpartum weight retention at 1 year postpartum, with approximately 47%
and 24% having retained 10lbs or more and 20lbs or more, respectively(115–117).
Additionally, postpartum weight retention is an independent predictor of long-term
weight gain, obesity and other negative short- and long-term maternal and neonatal
outcomes, including increased risk of type 2 diabetes and cardiovascular disease
(118,119).
Women who enter pregnancy with an overweight or obese BMI are less likely to
return to their pre-pregnancy BMI, compared to those with a normal BMI (116). Having
an overweight or obese BMI is associated with a greater likelihood of increased PPWR
(115–117). Additionally, excessive gestational weight gain (GWG) is often associated
with PPWR. The Institute of Medicine’s GWG recommendations for women with a prepregnancy BMI of overweight or obese guide women to gain less weight compared to
those with a normal or underweight pre-pregnancy BMI making it easier for overweight
or obese women to gain excessively during gestation (120). PPWR is has also been
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associated with a younger age at pregnancy, lower parity, not breastfeeding, lack of sleep
and lack of exercise (115,121,122).

2. Physiological Impact of Lifestyle Behaviors on Postpartum Weight Retention
Participation in regular physical activity and eating a quality diet have been
associated with the negative balance between caloric intake and expenditure necessary to
reduce weight (123).
During pregnancy, a woman’s body fat stores increase by approximately 1.95.8kg during pregnancy to aid in the growth and nourishment of the baby (124).
However, women also lose muscle tone due to stretching of the abdominal and pelvic
muscles (125). One pound of muscle burns approximately 35 calories whereas one pound
of body fat burns approximately 2 calories (126). Therefore, for postpartum women to
create a negative balance and decrease PPWR, it is necessary to build muscle through
physical activity and consume less calories through a quality diet during the postpartum
period.
Walking and strength training during the postpartum period help by increasing
metabolism and building calorie-burning muscle, while a nutritious diet high in energyrich complex carbohydrates, protein and healthy fats will help to decrease hunger and
maintain energy levels (127).
In terms of psychosocial mechanisms impacting energy balance, physical activity,
and diet logs aid in decreasing PPWR as they help achieve a negative caloric balance by
tracking intake and expenditure of calories.
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3. Clinical Trials of Lifestyle Interventions on Postpartum Weight Retention
Seven randomized controlled trials have examined the effects of lifestyle
interventions which commenced in pregnancy on postpartum weight retention (128–
134).Of these studies, five were conducted in the United States (15–18, 20) while two
were conducted in Northeastern Europe (132,134). Additionally, only three studies
contained some proportion of Hispanic women in their study population (128,130,131)
and four studies were limited to overweight and/or obese women (129,130,133,134) with
an additional two studies performing subgroup analyses among those who were
overweight and/or obese (128,131).
Three of the interventions were initiated during pregnancy and completed during
the postpartum period (128–130) while the remaining four interventions were conducted
exclusively during pregnancy (131–134). All but one of the interventions contained both
physical activity and dietary modifications (128,129,131–134). Of the six studies that
included a physical activity component all promoted moderate to vigorous physical
activity for a set amount of time per week, offered physical activity classes, or set
walking goals per day (128,129,131–134). All of the studies incorporated dietary
modifications as part of the intervention; the dietary modifications ranged from following
specific diets (including the American Diabetes Association diet, low-carb and reduced
sodium diets), overall reduction in calories from fat and limiting junk foods, providing
individualized meal plans and dietary counseling, and providing a cooking class (128–
134). Additionally, all the control groups involved in these studies received standard care
introducing the possibility that they were not contacted at the same frequency as those
who were in the intervention group. Only one study relied upon theoretical models,
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specifically the Social Cognitive Theory and the Transtheoretical Model, when
developing their intervention (128). Lastly, three of the studies’ interventions required
participants to go to a location making the intervention itself less accessible and most
cost-prohibitive than at-home interventions (132–134).
In terms of study findings, three studies found that the intervention group was
significantly more likely to be at or below their pre-pregnancy weight at 6 months
postpartum (129) or 12 months postpartum (131,132), but not both. Each of the three
studies that found that the intervention was significantly associated with a return to prepregnancy weight at 6 months or 12 months postpartum relied on either self-report or
electronic medical records to obtain information on pre-pregnancy weight. One study
found that the intervention group significantly gained weight between 2 weeks and 12
months postpartum (133) while another study found that there was a significant decrease
in PPWR among those women with a GWG less than or equal to 9kg compared to greater
than 9kg (134). The remaining two studies found no effect of the intervention on PPWR
at 6 months and 12 months postpartum (128,130).
The Peccei et al. study performed a 2-arm randomized controlled trial among 104
women in the United States, limited to those who were overweight or obese, 46% of
whom were Hispanic (130). Women who were randomized into the intervention arm
participated in a pregnancy and postpartum dietary modification that included culturally
appropriate bi-monthly counseling sessions on a low-carb diet, individualized meal plans,
weight gain trajectories and counseling on food labels, shopping for healthy foods,
calorie comparisons and supplement advice (130). The control group received standard
care (130). This study was not developed with a theoretical framework (130). When
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comparing the intervention and control arms, this study found no difference in the change
in weight at 6 weeks nor 6 months postpartum. However, among overweight women, the
intervention was associated with a lower percent of the initial BMI at 6 months
postpartum, compared to the control group (101% vs. 106%, diff= -4.9% (95% CI: -8.8, 0.9) (130). But this study provided a dietary modification only intervention which has
been shown to have a lesser effect on postpartum weight retention than interventions that
incorporate both physical activity and dietary modifications. Additionally, the control
group was provided standard care likely meaning that they were not contacted with the
same frequency and/or duration as the intervention group; by not controlling for contact
among the control group, there is the possibility that this could cause the differences
shown in weight via a social support mechanism. Lastly, although this study states that
they had a culturally appropriate and individualized intervention, it’s unclear what that
entails given that only 46% of the study population was Hispanic.
In summary, the prior epidemiologic studies of lifestyle interventions on
postpartum weight retention had several limitations: 1) most studies did not include
Hispanic women and those that did were comprised of less than 50% of this high-risk
group, 2) only three of the studies’ interventions occurred in both pregnancy and
postpartum period, and 3) all the control groups in these studies were provided standard
care. Therefore, we evaluated the effect of a physical activity and dietary intervention on
postpartum weight retention among approximately 100 Hispanic women, identified as
overweight or obese, in Massachusetts during early pregnancy through one year
postpartum. The lifestyle intervention is culturally modified, motivationally targeted, and
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individually tailored to Hispanic women and information was provided at the same
frequency to the control group as the intervention group, to control for contact time.

4. Summary of Significance and Innovation
Obesity is a risk factor for several diseases including diabetes and cardiovascular
disease; Hispanic women are more likely to be overweight or obese compared to their
non-Hispanic white peers (135). However, it is well established that improving lifestyle
behaviors, such as physical activity and diet, can reduce the obesity burden (136).
Therefore, we evaluated the effect of a culturally modified, motivationally targeted and
individually tailored lifestyle intervention on postpartum weight retention among
overweight and obese Hispanic women. This study is significant in that it targets an
ethnic group that has high rates of modifiable risk factors for postpartum weight retention
(e.g., physical inactivity and overweight or obese pre-pregnancy BMI) by intervening at
the beginning of the prenatal period and continuing through postpartum. Additionally,
this approach is innovative due to its utilization of a theory-based, individualized
lifestyle intervention in a minority population that includes novel materials to target
postpartum weight loss and would be readily translatable into clinical practice in this
high-risk population at a low cost.

B. Specific Aims and Hypotheses
Specific Aim #1: Evaluate the impact of a lifestyle intervention on postpartum weight
loss among overweight and obese Hispanic women.
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Hypothesis #1: Participants randomized to the LI arm will have greater
postpartum weight loss at 6 and 12 months postpartum as compared to
participants randomized to the comparison HW arm.
Hypothesis #2: Participants randomized to the LI arm will be more likely to
achieve IOM guidelines for postpartum weight retention when compared to
women randomized to the comparison HW arm.

C. Study Design and Methods
1. Study Design
Proyecto Mamá was a randomized controlled trial designed to test the efficacy of
a culturally and linguistically modified, individually tailored lifestyle intervention to
increase postpartum weight loss among overweight and obese Hispanic women. Eligible
women were recruited in early pregnancy (~10 weeks gestation) and randomly assigned
to either a Lifestyle Intervention (treatment arm) or a Comparison Health and Wellness
Intervention (control arm) (Figure 2). Randomization occurred at ~12 weeks gestation,
after completion of the baseline assessment, and was stratified based on age and prepregnancy BMI. The intervention began with an Active Intervention Period (i.e., ~12
weeks gestation through 6 months postpartum), followed by a Follow-Up Period (i.e., 6
months postpartum through 12 months postpartum). All protocols were approved by the
Institutional Review Boards at the University of Massachusetts Amherst and Baystate
Health.
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2. Study Population
Proyecto Mamá was conducted at the ambulatory obstetrical practices of Baystate
Medical Center located in Western Massachusetts. Inclusion criteria included pregnant
Hispanic women in early pregnancy (~10 weeks gestation) who were overweight or
obese (BMI >= 25 kg/m2) and 18-45 years of age. Exclusion criteria included: 1) prepregnancy BMI <25 kg/m2, 2) history of type 2 diabetes, heart disease, or chronic renal
disease, 3) contraindications to participation in moderate physical activity or to a lowfat/high-fiber diet (e.g., Crohn’s disease, ulcerative colitis), 4) inability to read English or
Spanish at a 6th grade level, 4) <16 or >45 years of age, 5) >16 weeks gestation, 6)
current medications which adversely influenced glucose tolerance, 7) not planning to
continue to term or deliver at the study site, or 8) a non-singleton pregnancy (e.g., twins,
triplets, etc.).

3. Intervention
The Lifestyle Intervention was an evidence-based approach utilizing culturally
and linguistically modified, motivationally targeted, individually-tailed intervention
materials developed in previous randomized controlled trials in Hispanic populations
(63–66,104–107) as well as theoretical concepts and strategies from the Social Cognitive
Theory (108) and the Transtheoretical Model (68).
First, the Prenatal Phase (~12 weeks gestation to delivery) began with a face-toface introductory session, which built upon the usual prenatal care received by patients.
The goal of this session was to optimize gestational weight gain via setting a gestational
weight gain goal, provide individually tailored encouragement and resources for how to
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meet that goal via better regulation of personal diet and exercise behaviors. Motivational
interviewing was used to identify and strengthen participants’ motivations for change.
Over the remainder of pregnancy, biweekly and monthly mailed print-based materials
and telephone booster calls were used to provide motivationally based individualized
feedback. Based on responses to the monthly mailed tailoring questionnaires,
individualized reports were sent to participants, in preferred languages at an accessible
reading level. The Prenatal Phase ended with a third trimester face-to-face session (~34
weeks gestation) to target participants’ knowledge and attitudes regarding postpartum
weight loss and type 2 diabetes prevention, preparing for the Active Postpartum Phase.
Second, the Active Postpartum Phase (6 weeks postpartum to 6 months
postpartum) began with a face-to-face session. At this session, the tailoring
questionnaires were repeated and individualized physical activity, dietary and weight loss
goals based on pre-pregnancy BMI were set. Participants were encouraged to work
towards their goals via reinforcement of their own weight loss motivations. This face-toface session was followed by monthly mailed, print-based materials and telephone
booster calls to provide motivationally based individualized feedback incorporating
progress review, problem-solving discussion, and goal setting assistance.
Lastly, the Maintenance Postpartum Phase (6 months to 12 months postpartum)
continued with mailed, print-based materials and telephone booster calls, as in the Active
Postpartum Phase, but at a lesser frequency.
At the start of the intervention, the postpartum weight loss goal was a 5%
reduction from pre-pregnancy weight. This was based on IOM guidelines for postpartum
weight loss, a modified version of the Diabetes Prevention Program (DPP) and prior
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weight loss interventions (120,128,137). Health educators encouraged this overall
postpartum weight loss by focusing on a weight reduction of 1-2lbs/week among the
Lifestyle Intervention arm. The health educators also used motivational materials that
provided information on motivators for wanting to lose weight, directed at new mothers,
highlighting benefits of weight loss. Additionally, mailed materials were sent during the
Active Postpartum Period and the Maintenance Postpartum Period that included
strategies for eliciting family and social support for weight loss and tips for managing
fluctuations in weight loss over time.

4. Comparison
The Health and Wellness comparison arm received mailed health materials and
telephone booster calls at the same frequency as the Lifestyle Intervention participants, to
control for contact time. However, materials focused on non-exercise and non-dietary
topics, so the content remained distinct from that provided to the Lifestyle Intervention
arm. The weight loss information provided to the Health and Wellness comparison arm
focused on the recommendations provided by the IOM.

5. Outcome Variables: Postpartum Weight Retention
Women were provided with accurately calibrated standard clinical scales to chart
their weight. Postpartum weights at 6 weeks, 6 months and 12 months were self-reported
to the nearest 0.1kg.
Primary Outcome: Change in weight was calculated as the difference between
pre-pregnancy weight (baseline) and weight at 6 and 12 months postpartum, respectively.
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Pre-pregnancy weight was abstracted from the medical record or self-reported at the time
of recruitment, while postpartum weight was measured prospectively at home by
participants based on their provided scale. Change in weight was calculated on a
continuous scale.
Secondary Outcome: Additionally, we assessed the percentage of participants
who retained less than 5% of their pre-pregnancy weight, consistent with the goal of this
study. We compared the proportion of participants who achieved this goal in the two
arms of the study at 6 weeks, 6 months, and 12 months postpartum. Postpartum weight
retention was calculated as a dichotomous outcome.

6. Covariate Measures
Medical history variables included personal history of GDM, family history of
diabetes, previous infant with abnormalities, and parity. Each of the medical history
variables are presented categorically.
Clinical characteristics of the current pregnancy were abstracted from the medical
record and included glucose tolerance and diagnosis of hypertension, preeclampsia, and
gestational weight gain. Glucose tolerance test results were categorized as normal,
isolated hyperglycemia, impaired glucose tolerance, and gestational diabetes mellitus
(138). Gestational weight gain was categorized as below, within, or above the Institute of
Medicine’s guidelines (113).
Sociodemographic measures were collected from self-report and included income,
level of education, health insurance status, and generation in the US. Acculturation was
also measured via the Psychological Acculturation Scale (80) and were categorized as
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low acculturation (scoring 1 to less than 3 on the scale) or high acculturation (greater than
3 on the scale).
Smoking status was assessed via cotinine, the major metabolite of nicotine.
Additionally, alcohol consumption and drug use were collected via questions from the
Pregnancy Assessment Monitoring System. Pregnancy and postpartum sleep were
collected via the Pittsburgh Sleep Quality Index (PSQI). Pregnancy and postpartum
depression were measured using the Edinburgh Postpartum Depression Scale, validated
for Hispanics (111,139).

D. Data Analysis
Specific Aim #1: Evaluate the impact of a lifestyle intervention on postpartum weight
loss among overweight and obese Hispanic women.

1. Univariate Analyses
We present the number and percent of subjects who are in the original sample,
who are lost to follow-up, and who are in the final analytic sample (Figure 2). We also
present the number and percentage of participants randomized to the two intervention
arms (Table 3.1) and weight at pre-pregnancy, late pregnancy, 6 weeks, 6 months and 12
months postpartum (Table 3.2).

2. Bivariate Analyses
We present the baseline characteristics of the two intervention arms using twosample t-tests and chi-square tests to determine if there were different distributions
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between the arms at baseline (early pregnancy) (Table 3.3). All tests will be two-tailed,
and the level of significance will be p<0.05. Covariates that do not significantly differ
between the arms will not be included in primary analyses.
Primary Outcome: We present the average pre-pregnancy weight and postpartum
weight loss by randomization arm at late pregnancy, 6 weeks, 6 months, and 12 months
postpartum and the change in weight from baseline to each time point postpartum (Table
3.4).
Secondary Outcome: Additionally, we present the proportion of participants who
achieved a 5% reduction from pre-pregnancy weight, by randomization arm (Table 3.5).

3. Multivariable Analyses
An intent-to-treat analysis was conducted.
Primary Outcome: T-tests were used to compare weight change differences within
and between arms over time. Generalized linear mixed-effect models (using the
intervention arm as a fixed effect, subjects as a random effect, and an unstructured
covariance matrix) were used to evaluate differences in the change in weight from prepregnancy to late pregnancy, 6 weeks, 6 months, and one year postpartum between the
intervention arms (Table 3.4). A group by time interaction term was used to test whether
change in weight differs significantly with time.
Secondary Outcome: To evaluate differences in the percentage of women meeting
the secondary outcome of postpartum weight reduction between arms over follow-up,
logistic regression models and generalized linear models were used (Table 3.5).
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All multivariable models were adjusted for baseline characteristics that
statistically significantly differed between arms.

Multiple Imputation Analyses:
Missing postpartum weights were imputed in the manner of prior weight loss
trials with the use of 10 random multivariate imputations based on observed variables at
baseline (Tables 3.4 and 3.5).

4. Sensitivity Analyses
We performed a few sensitivity analyses. First, we presented the baseline
characteristics of those who remained in the study compared to those who were lost to
follow-up (Table 3.6). We also limited the analysis to women in the LI who were
compliant with the intervention defined as: 1) meeting the ACOG exercise guidelines and
2) returning >1 tailoring questionnaires during the postpartum period to evaluate whether
receiving the planned dose of the intervention affects differences in postpartum weight
loss between the intervention arms (Tables 3.7 and 3.8). Additionally, we stratified
results on gestational weight gain to evaluate whether the impact of the lifestyle
intervention had differing effects on postpartum weight retention across varying levels of
gestational weight gain (Tables 3.9 & 3.10). We also evaluated the impact of actual
physical activity on postpartum weight regardless of assigned intervention arm,
generalized linear models were used to assess the impact of self-reported sports/exercise
(Table 3.11) and combined moderate-vigorous intensity (Table 3.12) on the primary and
secondary outcome variables. These models were adjusted for pre-pregnancy BMI (140).
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Lastly, we assessed whether participants who were adherent to ACOG guidelines of
physical activity, regardless of the assigned intervention arm, had different distributions
of covariates at baseline as compared to those who were non-adherent to ACOG
guidelines of physical activity (Table 13).

E. Results
The final analytic sample included 49 participants in the LI arm and 52
participants in the HW arm (Table 3.1). There were no statistically significant differences
between participants in the LI and HW arms according to sociodemographic, medical
history, behavioral, or acculturation covariates (Table 3.3).
We evaluated the mean changes in weight from prepregnancy to late pregnancy
and postpartum within each intervention arm (Table 3.4). In both the LI and HW arms,
mean weight increased from prepregnancy through late pregnancy (7.94kg, 95% CI:
4.90-10.97 and 10.38kg, 95% CI: 7.44-13.32, respectively) and 12 months postpartum
(5.47kg, 95% CI: 1.16-9.77 and 6.84kg, 95% CI: 3.54-10.13, respectively) (Table 3.4).
However, only the HW arm experienced a significant increase in mean weight from
prepregnancy to 6 weeks and 6 months postpartum (2.68kg, 95% CI: 0.72-4.64 and
5.51kg, 95% CI: 2.73-8.30, respectively) (Table 3.4).
We then evaluated the mean differences in weight change between the
intervention arms (Table 3.4). There were no differences in weight change between the
LI and HW group at late pregnancy, 6 weeks, and 12 months postpartum. However, we
observed statistically significant mean differences in weight at 6 months postpartum
between arms, with the LI arm experiencing a greater decrease in weight at that time
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point (-4.78kg, p=0.03) (Table 3.4). When evaluating the average effect of the
intervention across all time points, we observed a non-statistically significant -1.59kg
mean weight difference between the LI and HW arms, adjusting for prepregnancy weight
(-1.59kg, 95% CI: -4.32, 1.14) (Table 3.4).
We then evaluated findings using imputed postpartum weights for those missing
weights. As in the primary analysis, both the LI and HW arms experienced significant
increases in weight during late pregnancy. However, only the HW group experienced
significant increases in weight to from prepregnancy to 6 weeks, 6 months, and 12
months postpartum of similar magnitude as in the primary analysis (Table 3.4). In
contrast to the primary analysis, however, there were no significant mean differences in
weight change between the intervention arms in this analysis (Table 3.4). When
evaluating the average effect of the intervention across all time points, we observed a
non-statistically significant -2.17kg mean weight difference between the LI and HW
arms, adjusted for prepregnancy weight (-2.17kg, 95% CI: -5.16, 0.83) (Table 3.4).
Next, we evaluated whether the proportion of women meeting the 5% reduction in
prepregnancy weight goal differed between the intervention arms (Table 3.5). Using
generalized estimating equations to evaluate differences between arms across follow-up
time points, women in the LI arm had an approximately 5.5 times higher odds of meeting
the weight reduction goal compared to the HW arm, (aOR=5.45, 95% CI: 1.66-17.86)
adjusting for prepregnancy weight. However, when using the imputed postpartum
weights, this associated was attenuated and no longer statistically significant (aOR=2.52,
95% CI: 0.98-6.47).
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We then conducted several sensitivity analyses. First, we evaluated whether there
were differences in the baseline characteristics between those women who were lost to
follow-up compared to those who were not (Table 3.6). While women who were lost to
follow-up did not differ in terms of medical history, behavioral, and acculturation
variables, they were older and less likely to have 3 or more adults in the household (Table
3.6).
Secondly, we evaluated whether findings for weight change differed according to
adherence with the intervention defined as compliance with the ACOG guidelines for
sports/exercise (73% of the LI arm) or the return of the tailoring questionnaires (73% and
89% in the LI and HW arms, respectively) during the postpartum period (Tables 3.7 &
3.8). When examining mean weight change among those who were ACOG compliant and
the odds of meeting postpartum weight goals, findings were virtually unchanged in this
per protocol analysis (Tables 3.7 & 3.8). However, there were no differences in findings
among those who were compliant with returning tailoring questionnaires (Table 3.7).
Additionally, when comparing the characteristics of those who were adherent to the
ACOG guidelines, compared to those who were not adherent, we observed no differences
in the distribution of covariates across the groups (results not shown).
Third, we evaluated whether our findings differed among women according to
compliance with gestational weight gain guidelines (i.e., inadequate/adequate or
excessive gestational weight gain); findings were attenuated (Tables 3.9 & 3.10).
Lastly, we evaluated whether different types and intensities of physical activity,
as opposed to assigned intervention arm, were associated with weight change and
meeting the postpartum weight goals (Tables 3.11 & 3.12). Those who participated in
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sports/exercise activity above the median had an approximately 4 times higher odds of
meeting postpartum weight goals, compared to those who participated at or below the
median (OR=4.19, 95% CI: 1.06-16.55) (Table 3.11); this association was attenuated but
remained statistically significant when using the imputed postpartum weights (OR=3.02,
95% CI: 0.76-11.97). No other types or intensities of physical activity were statistically
significantly associated with these outcomes. (Table 3.12).

F. Discussion
In this randomized controlled trial of a lifestyle intervention among overweight
and obese Hispanic women, we observed a clinically significant 5.5-fold higher odds of
meeting postpartum weight reduction goals among the LI arm compared to the HW arm
at one year postpartum. In addition, the LI arm experienced a 5 kg (i.e., 11 pound)
smaller increase in weight as compared to the HW arm at 6 months postpartum.
However, this improved performance of the LI group in terms of weight change did not
persist to 12 months postpartum.
In terms of meeting postpartum weight reduction goals, our results were
consistent with some (129,132) but not all the prior randomized trials that evaluated this
outcome (128,131,134). Similar to our findings, Herring et al. observed that the
intervention arm was more likely to be at or below their early pregnancy weight than the
control arm at 6 months postpartum in a population of overweight/obese African
American women (aOR: 3.5, 95% CI: 1.0, 11.8)(129). Similarly, Sagedal et al. observed
that the intervention arm was more likely to return to pre-pregnancy weight than the
control arm at 12 months postpartum (OR: 1.5, 95% CI: 1.0, 2.24) in a population of
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Norwegian women (132). Consistent with these findings, in the current study, we
observed that the lifestyle intervention led to a higher odds of reducing weight to 5%
below pre-pregnancy weight across all postpartum time points (OR: 5.5, 95% CI: 1.7,
17.9). In contrast, the studies by Ferrara et al., Phelan et al., and Vinter et al. did not
observe a significant impact of the intervention on meeting postpartum weight reduction
goals (128,131,134). The difference in findings between the current study and prior
studies could be due to differences in the timing and duration of the lifestyle intervention;
two of the prior non-significant studies were conducted solely during pregnancy for
approximately 24-30 weeks (131,134), while the other did not commence until late in
pregnancy at the time of GDM diagnosis and continued through 12 months postpartum
for a total of approximately 15 months (128). In contrast, the current study’s intervention
was conducted from early pregnancy through 12 months postpartum for a total of
approximately 19 months.
In terms of our secondary outcome of postpartum weight retention, our findings
for a significantly lesser weight gain at 6 months postpartum between the LI and HW
arms are consistent with some (131) but not all the randomized trials that evaluated this
outcome (130,132). Phelan et al. observed a 1.6 kg difference between the arms at 12
months postpartum (1.4 kg vs 3.0 kg) which is similar to our findings of a 4.52 kg
difference at 6 months postpartum (0.7 kg vs. 5.5kg) although we observed no significant
differences at 12 months postpartum. The studies by Peccei et al. and Sagedal et al.
observed no significant differences in postpartum weight change between the intervention
and control arms; however, in a sensitivity analysis, Sagedal et al. did observe a
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significant 1.54 kg lower postpartum weight retention among compliant intervention
participants compared to control participants (130,132).
There are several possible explanations for our findings that the impact of the
lifestyle intervention on weight change did not persist after 6 months postpartum. First,
during the postpartum period, women report several barriers to performing physical
activity due to the stressors related to being a new mother (141). Women in the LI arm
may have received sufficient supports from study personnel during the first 6 months
postpartum resulting in greater weight reduction. However, the study’s active phase
ended at 6 months postpartum, where the social support provided by regular contacts with
study personnel were replaced by regular mailings. This reduction in support could have
caused women to minimize their regular physical activity and consumption of a quality
diet. It is well recognized that to lose weight postpartum, women need to reach a calorie
deficit which can be reached by participation in regular physical activity and eating a
quality diet, which can be supported by tracking activity and diet. Second, it is possible
that there was insufficient statistical power for evaluation of postpartum weight retention
at the 12 months postpartum as the study experienced 54% attrition at that time point.
This study has several limitations. First, non-differential misclassification of the
assigned intervention arm could have occurred in the per protocol analysis. Participants
who had been randomized to the LI arm could have performed little physical activity and
dietary modifications, while participants who had been randomized to the HW arm could
have performed recommended levels of physical activity and dietary modifications. This
is likely to have occurred, given that not all participants randomized to the intervention
will follow the provided recommendations and intervention, while participants
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randomized to the control group may change their habits regardless of the study or due to
the social supports provided. Specifically, we observed that 27% of the LI arm did not
meet the ACOG guidelines at any time postpartum, while 53% of the HW arm did.
However, we observed no differences in the distribution of covariates among those who
were ACOG compliant compared to those who were not. Additionally, this study’s
utilization of a control arm matched for contact time minimizes the concern that social
support alone led to any observed changes, as opposed to changes being due to the
lifestyle content of the intervention. Finally, to the extent that non-differential
misclassification of the assigned intervention arm occurred, it would bias the results
towards the null. However, our allocation system, utilized by the health educators and
assessors, makes this concern highly unlikely (103).
Additionally, non-differential misclassification of postpartum weight retention
could have occurred if weight measurements, abstracted from the medical record and
self-reported, were inaccurate. This is likely to have occurred despite the high validity of
weights abstracted from the medical record among obese women (142) since women tend
to underestimate their weight when self-reporting (143,144). This would bias the results
towards the null.
Despite the substantial loss to follow-up in this study (25%), differential loss to
follow-up is unlikely to have occurred since we observed similar loss to follow-up for
both randomization arms (LI: 67%, HW: 75%). This, in combination with the comparable
distribution of covariates among those who were included in the analysis group and those
who were missing all postpartum weight measures, minimizes the concern about
differential loss to follow-up.
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Information bias, where information on postpartum weight retention was obtained
differently between the two treatment arms or where one arm was followed more closely
than the other, is unlikely to have occurred in this study. The methods for obtaining and
measuring weight and postpartum weight retention were the same for both treatment arms
and assessors of weight were blinded to the treatment arm of participants.
Confounding is unlikely to have affected this study due to the use of
randomization. When comparing the distribution of covariates between the intervention
arms, we observed no differences in covariate distributions. However, it is possible that
randomization did not result in the comparable distribution of unknown covariates and
therefore, residual confounding could remain.
Lastly, due to the cultural tailoring of the provided intervention and the restriction
to overweight or obese women, the results of this study should be limited to other
Hispanic postpartum women who had an overweight or obese BMI during pregnancy.
In summary, in this randomized controlled trial of a culturally tailored,
individually modified lifestyle intervention among overweight and obese Hispanic
women we observed a clinically significant 5.5-fold increased odds of reducing weight to
less than pre-pregnancy weight and a positive impact on reducing postpartum weight
retention at 6 months postpartum. These findings suggest that an active lifestyle
intervention among at-risk Hispanic women has a beneficial impact on postpartum
weight reduction, but these effects may not be sustained long-term. Future studies should
continue to evaluate this association among at-risk minority women, incorporate active
social support throughout the intervention, and focus on promotion of meeting physical
activity guidelines.
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Table 3.1. Distribution of Participants Randomized to Intervention Arms; Proyecto
Mamá 2014-2017.

176

Table 3.2. Distribution of Weight at Pre-Pregnancy and Each Postpartum Time Point;
Proyecto Mamá 2014-2017.
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Table 3.3. Distribution of Covariates across the Lifestyle and Health & Wellness
Intervention Arms; Proyecto Mamá 2014-2017.

178

Table 3.3., continued
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Table 3.4. Mean Changes in Weight from Pre-Pregnancy Baseline to 12 Months Postpartum and Mean Differences between
Intervention Arms; Proyecto Mamá 2014-2017.
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Table 3.5. Proportion of Women Meeting 5% Weight Reduction Outcome with Odds Ratios Estimating Differences between
Intervention Arms; Proyecto Mamá 2014-2017.
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Table 3.6. Distribution of Covariates across Participants Included in the Analysis and
Participants Missing All Weight Data; Proyecto Mamá 2014-2017.
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Table 3.6., continued
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Table 3.7. Mean Changes in Weight from Pre-Pregnancy Baseline to 12 Months Postpartum and Mean Differences among Adherent
Participants; Proyecto Mamá 2014-2017.
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Table 3.8. Proportion of Women Meeting 5% Weight Reduction Outcome with Odds Ratios Estimating Differences among Adherent
Participants; Proyecto Mamá 2014-2017.
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Table 3.9. Mean Changes in Weight from Pre-Pregnancy Baseline to 12 Months Postpartum and Mean Differences between
Intervention Arms, Stratified on Gestational Weight Gain; Proyecto Mamá 2014-2017.
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Table 3.10. Proportion of Women Meeting 5% Weight Reduction Outcome with Odds Ratios Estimating Differences between
Intervention Arms, Stratified on Gestational Weight Gain; Proyecto Mamá 2014-2017.
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Table 3.11. Mean Changes in Weight from Pre-Pregnancy Baseline to 12 Months Postpartum and Proportion of Women Meeting 5%
Weight Reduction Outcome According to Participation in Sports/Exercise Physical Activity; Proyecto Mamá 2014-2017.
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Table 3.12. Mean Changes in Weight from Pre-Pregnancy Baseline to 12 Months Postpartum and Proportion of Women Meeting 5%
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